CURRICULUM VITAE Brian Herbert Harvey

A) SUMMARY: I am a registered pharmacist with an honours degree in pharmacology. I have undergone extensive experience in all major areas of pharmacy practice, viz. retail, hospital, industry (sales and marketing) and research. I have enjoyed considerable success in biomedical research and have acquired a M.Sc (cum laude) and Ph.D. with pharmacology as specialization, and a special interest in clinical and experimental neuro-and psychopharmacology. The results of my research have been published extensively in scientific literature (Annexure B) and/or presented at local and international congresses (Annexure A). This specialized expertise has prompted invitations from both local and international groups to give presentations, plenary lectures and guest lectures on this area or to prepare review papers for peer-reviewed international journals (Annexure G). My academic endeavor in experimental research was temporarily diverted by a three-year period (1994-1997) spent in the pharmaceutical industry where I developed extensive sales and marketing experience from within a multi-national pharmaceutical company. However, during this time, I developed a keen interest and involvement in clinical psychiatry research and became recognized within the medical fields of psychiatry and neurology. Upon re-entering academia in January 1998, I have begun to focus with intent on clinical and experimental research into the neurobiology of neurological and psychiatric illnesses. My expertise is in the development and application of translational animal models of human psychiatric disorders, specifically major depression, schizophrenia, posttraumatic stress disorder (PTSD) and obsessive compulsive disorder (OCD). I have developed an extensive international network of collaborators, but also in South Africa. I have a keen interest in the training and nurturing of young neuroscientists and pharmacologists, most notably at the masters degree and doctoral levels (Annexure D). In 2012 I received the FARMOVS prize for pharmacology and drug development from the Suid Afrikaanse Akademie vir Wetenskap en Kuns (South African Academy of Arts and Science). I currently hold a B2 rating by the National Research Foundation. I serve on various national advisory boards in my capacity as a neuroscientist and pharmacologist, and on the editorial boards of international professional journals (Annexure F and G), and act as reviewer for a number of international peer review journals (Annexure H). Based on my research publications and citations, I have a Hirsch (H)-factor of 27 (Publish or Perish/Google Scholar).

B) PERSONAL: 1. TELEPHONE : (W) 27 18-2992238 FAX : 27 18-2992225 E-MAIL : Brian.Harvey@nwu.ac.za PLACE OF BIRTH : Virginia, Freestate, South Africa DATE OF BIRTH : 26 April 1961 NATIONALITY : South African MARITAL STATUS : Married CHILDREN : Girl, born 13 June 1991

2

Boy, born 10 February 1995 LANGUAGES : English and Afrikaans (fully bilingual) CURRENT EMPLOYMENT: North-West University, Potchefstroom, North-West

Province, South Africa

2. PROFESSIONAL SOCIETY MEMBERSHIPS:

South African Neuroscience Society South African Society for Basic and Clinical Pharmacology South African Academy of Pharmaceutical Sciences Collegium International Neuropsychopharmacolgicum (CINP-Fellow) International Brain Research Organisation (IBRO) International Society for Lithium Research Serotonin Club Registered Pharmacist with the South African Pharmacy Council

3. OUTSIDE INTERESTS: Music, cycling, hiking, gym. I released my first music CD in June 2004.

C) SELECTED ACCOMPLISHMENTS:

1. North-West University, Potchefstroom:

Identified by the Chandler Medical Center, University of Kentucky, as a key person in South Africa to undertake and run a collaborative research project focusing on the development of new therapeutic agents against the human immunodeficiency virus.

Recipient of an International Brain Research Organization (IBRO) bursary to attend the Congress of the Federation of European Neuroscience Societies (FENS) in England from the 24th to 28th June 2000.

Awarded a “Poster Award” for scientific excellence (researchers under 40 years), at the Collegium Internasionale Neuro-Psychopharmacologicum (CINP) Congress in Brussels, Belgium, July 2000.

Appointed to the Committee for Research Evaluation at the University of Potchefstroom (Universiteitstoetsingkommissie) responsible for reviewing strategic innovation fund applications and, secondly, ensuring quality of research output and long-term viability of research focus areas within the university.

Program leader: Drug Research and Development focus area at the PU for CHE.

Invited to peer-review manuscripts for leading international journals.

Rated as a B2-scientist by the National Research Foundation (evaluation in 2010).

Appointed to the executive committee, South African Neuroscience Society. 2001-2009.

3

Appointed to the Peer-review Board of the South African Medical Research Council.

Elected to Fellowship of the Collegium Internationale Neuro-Psychopharmacologicum (CINP).

Awarded the Janssen-Cilag “Best Publication Award” in the Faculty of Health Sciences, North-West University, in 2003, 2004 and 2006.

Awarded the South African Academy of Pharmaceutical Sciences “Best Publication Award in Pharmacology” in 2001, 2002, 2004, 2006, 2009, 2010 and 2011.

Awarded the South African Pharmacology Society “Best Publication Award” in 2005, 2009, 2011 and 2013.

Research program evaluated and approved as an official affiliate of the MRC Unit on Anxiety and Stress Disorders, and subsequently appointed co-director for animal research for the unit in 2002.

Recipient of an International Union of Pharmacology (IUPHAR) Travel Award to attend the World Congress of Pharmacology in San Francisco, California, USA, on the 7-12th July 2002.

Appointed as member of the National Research Foundation (NRF) Assessment Panel, as well as the NRF Specialist Committee for Health Sciences, January 2003-December 2005.

Invited by the International Scientific Program Committee of the 24th Congress of the Collegium Internasionale Neuropsychopharmacologicum (CINP) to participate as a speaker in a synthesia held in Paris, France, from 20-24 June 2004.

Appointed to the editorials boards of South African Psychiatry Review, Human Psychopharmacology, Metabolic Brain Disease and Neuropsychiatric Disease and Treatment, the latter being the new official journal of the International Neuropsychiatric Association.

Invited by the International Scientific Program Committee of the 25th Congress of the Collegium Internasionale Neuropsychopharmacologicum (CINP) held in Chicago, USA, from 9-13 July 2006.

Invited to present a guest lecture, entitled “Stress and the brain: A new challenge for psychopharmacology”, at the Dept of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 20th September 2005.

Invited to present a visiting guest lecture at the Dept of Psychiatry & Behavioral Neurosciences, McMaster University, Hamilton, ON, Canada, on the 13th July 2006.

Appointed by Pfizer (SA) to the Ziprasidone Advisory Board, together with other leading South African psychiatrists and neuroscientists. The purpose of this advisory panel is to provide scientific and clinical expertise in the evaluation and treatment of schizophrenia, and to use this expertise to guide Pfizer‟s efforts in the appropriate and

ethical marketing of ziprasidone (Geodon), a new atypical antipsychotic agent.

4

Invited by Bristol Myers Squibb SA to deliver a key note address at the South African

launch of Abilify (Aripiprazole), a new antipsychotic agent.

Taken up into Marquis Who‟s Who 2006-2007 Edition of Who‟s Who in Health and Medicine

.

Appointed by Servier (SA) to the Agomelatine Advisory Board. The purpose of this advisory panel is to provide scientific and clinical expertise in the evaluation and treatment of depression, and to use this expertise to guide Servier‟s efforts in the appropriate and ethical marketing of agomelatine, a new class of antidepressant.

A number of my students win the Young Scientists Award by the South African Society for Basic and Clinical Pharmacology (see Local congress presentations).

Invited to write an authorative review on the role of glutamate receptors and glutamate signalling in anxiety disorders for a special issue of the noted international peer review journal, Pharmacology, Biochemistry and Behaviour (see Harvey and Shahid 2011 in publication list).

Invitated to write a commentary on the neurobiology of PTSD recently published in “Trauma and Mental Health: Resilience and Posttraumatic Disorders”, a Wiley-Blackwell publication under the auspices of the American Psychiatric Association (see Harvey 2011 in list of books).

Invitation from the noted international journal, Psychiatric Clinics of North America, to prepare a review paper on animal models of OCD (see Korff and Harvey 2006 in list of publications).

Invited presentation at a symposium on the Biomedical Pathophysiology Relevant to Stress and Disease at the 68th Annual meeting of the American Psychosomatic Society, Maritime Hotel, Portland, Oregon, USA. 11-13 March 2010.

Invited research report presented at the Agomelatine Master Class Symposium hosted by Servier Pharmaceuticals, 10-13th February 2010, Paris, France, entitled

“Antidepressant discontinuation and the benefits of agomelatine”. Harvey BH.

Invited by the Collegium Internasionale Neuropsychopharmacologicum (CINP) to present a plenary lecture at the CINP Psychopharmacology course, Johannesburg (2-3rd April 2011) and Cape Town (12-14th Nov 2010), South Africa.

Invited to contribute a chapter entitled “The Neurobiology of Psychiatric Disorders” in Textbook of Psychiatry 2nd edition, published by Oxford University Press and due for publication in 2014.

In 2012 I received the FARMOVS prize for pharmacology and drug development from the Suid Afrikaanse Akademie vir Wetenskap en Kuns (South African Academy of Arts and Science).

Invited by the organisers of 11th World Congress of Biological Psychiatry, held in

Kyoto, Japan, 23-27 June 20-13, to chair a symposium entitled “Novel approaches

5

for the treatment of unipolar depression”, as well as to present a talk on “N-acetyl cysteine as a novel treatment for depression”.

2. Eli Lilly:

Prepared a paper on „Suicide and Prozac‟ that presented the scientific facts on Prozac (fluoxetine) and its purported involvement in suicidal ideation. This document was distributed to representatives in the field who became far more confident to address the issue. It was welcomed with enthusiasm and counteracted negative publicity amongst doctors and members of the public.

Permax, a product for Parkinsons‟ Disease was inadequately marketed. I "re-launched" the drug in specific sales areas via presentations on the pathology of Parkinson‟s disease and why Permax is unique. Uptake and recognition was excellent, boosting sales of the product many fold. Following my success with Permax, the company asked me to prepare a new detail visual aid for the representatives based on my strategies. The final result was accepted with enthusiasm from management and representatives alike.

Researched, designed and presented a lecture series for doctors and registrars on the role of serotonin in the mechanism of action of various antidepressants. Doctors received a copy of comparative laboratory and clinical data that would clearly indicate the most important clinical differences among the different agents. The aim was to assist the clinician in making a rational choice of antidepressant drug based on sound scientific and clinically relevant data. The complete work was later published in the

South African Medical Journal (S Afr Med J (1997); 87, 540-552). The paper has also been recognized internationally by recently being approved by the global marketing division of Eli Lilly, Indianapolis, USA, for world wide use by representatives as factual scientific support of marketing claims.

The use of drugs in children, especially psychiatric drugs, is a high-risk area. Few controlled trails are allowed in this age group. However, I initiated a peer-reviewed action group who would meet quarterly to discuss psychopharmacology and therapeutics in children. The result of this was clinicians in the area of child psychiatry were now able to make more informed decisions on using a particular drug in a child, thereby promoting a more favorable outcome. The group has since been named the Child & Adolescent Psychopharmacology Group and functions under the auspices of the S.A. Association for Child and Adolescent Psychiatry and Allied Professions.

3. Tygerberg Hospital:

Initiated and built up a clinical pharmacy ward round programme for interns with consultants in the departments of Internal Medicine and Pediatrics. This activity later led to journal club meetings and ultimately led to a major improvement in intern motivation and morale, as well promoted outside interest in the department. It also significantly enhanced clinical training for intern pharmacists.

D) EXPERIENCE (DUTIES):

6

1. ASSOCIATE-PROFESSOR (January 1998-December 2001), and FULL

PROFESSOR (January 2002-present), DIVISION OF PHARMACOLOGY, SCHOOL

OF PHARMACY, NORTH-WEST UNIVERSITY (NWU)

RESEARCH: As Program leader within the Drug Research and Development focus area at the NWU, I am project leader on various post-graduate Masters and Doctoral projects. My research group has published extensively in peer-reviewed, international journals (Annex B) and has presented our data at various national and international congresses (Annex A). I have extensive international research collaborations in the USA, Denmark and Australia as well as locally in South Africa (Annex J) At NWU, I am conducting research in clinical and experimental neuro- and psychopharmacology, with my current research interests being behavioral and molecular neuroscience and neuro-psychopharmacology. Recent and current projects include the neurobiology of schizophrenia, tardive dyskinesia, post-traumatic stress disorder, obsessive compulsive disorder, anxiety and depression. The emphasis of these projects is on behavioral validation focusing on a number of cognitive behavioural models, including the Morris water maze, conditioned taste aversion, contextual fear conditioning, prepulse inhibition of startle, elevated plus maze and various assessments of locomotor and stereotypic behaviors. I have a special interest in the role of biogenic amines, the nitric oxide pathway, glutamate, GABA and cellular resilience molecules in these models. As I am a pharmacologist, drug treatment protocols are included in order to study possible noval drug targets, and also to validate the behavioral models. We are also currently exploring genetic models of depression and OCD. Studies use both in vivo animal models as well as in vitro cell culture models. There is a strong emphasis on molecular pharmacology using western blot and polymerase chain reaction (PCR) techniques, and we also employ a number of radiometric and analytical techniques. Genetic animal models that allow the study of distinct neuro- and behavioral pathology akin to that of the human disorder are also used. Typical parameters that are studied include nitric oxide synthase, lipid peroxidation, superoxide dismutase, receptor-binding studies, second messenger determination (eg cAMP, cGMP, inositol phosphates etc), G-protein signaling and cell death/survival proteins, as well as immune-inflammatory cascades. Behavioral tests employed include the assessment of anxiety, depressive behavior, spatial memory, acoustic startle, social interaction and locomotor behavior. Other notable research activities and achievements include evaluation and rating by the National Research Foundation (NRF) as a C2-rated scientist in 2000, increased to C1 in 2005, and to my current B2 status since 2010. Notable appointments include the peer-review board of the South African Medical Research Council (MRC), as well as the peer--review panel for Health Sciences, at the National Research Foundation, as well as appointment as Co-director for Animal Models Research at the MRC Unit on Anxiety and Stress Disorders, Cape Town, South Africa. I was elected to Fellowship of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) in 2001. I have been appointed reviewer for a number of well-recognized international peer-review journals and also have been appointed on the editorial boards of a number of international professional journals (Annex F). TEACHING

Within the school of Pharmacy at NWU, I have designed, and established study guides on modules covering central nervous system and endocrine pharmacology, and currently lecture in these areas to BPharm under-graduates (2nd-4th year). I am also Module co-ordinator and/or writer and facilitator for various modules of the web-

7

based telematic BSc honours program in pharmacology presented by our school. These modules include CNS pharmacology, endocrine pharmacology, a module on neuropsychoimmunology and a module on clinical trials. This BSc Hons program attracts students both locally in South Africa and abroad because of its telematic, web-assisted design. Due to my recognized expertise in the area of psychopharmacology, I have been invited on various occasions by pharmaceutical companies (eg Eli Lilly and Pfizer) to lecture to medical practitioners and medical specialists on areas of neuro-psychopharmacology, especially that pertaining to the pharmacology of schizophrenia and depression. I currently serve on the Pfizer

Ziprasidone (Geodon) Advisory Board (2002 – present). Other academic activities at NWU of note include my appointment to the Faculty Board, Faculty of Pharmacy, North-West University (1998), member of the Convocation, North-West University (current), member of the Research Committee, Faculty of Pharmacy, North-West University (current), member of the Animal Research Center Control Board, North-West University, member of the ethical advisory board of NWU (2000-2003), member of the HIV/AIDS Task team, North-West University and member of the Evaluation Committee for Research at North-West University (2000-2002).

2. CNS PRODUCTS ADVISOR, ELI LILLY (S AFR) (May 1994 – August 1997) The principle requirement of this position was to call on specialist doctors, notably psychiatrists and neurologists, to promote the use of Eli Lilly products. In addition to the required sales activities, I performed the following functions:

Advisor/consultant to psychiatrists and neurologists (including registrars in these disciplines).

Preparing and presentation of continuing medical education lectures to psychiatrists and neurologists, including registrars.

Marketing and product information support to Eli Lilly representatives and their clients, usually general practitioners, nurses and other paramedical personnel.

Writing up novel clinical observations and collaboration with clinicians, for publication in the scientific literature.

3. SENIOR SCIENTIST, MRC CENTRE FOR MOLECULAR AND CELLULAR

BIOLOGY (January 1994 - April 1994) Closure of the MRC Research Unit for the Neurochemistry of Mental Diseases by the Medical Research Council (MRC) in late 1993, prompted the decision to pursue post-doctoral studies in a new direction of research, viz. in infection and immunology. A tentative protocol, entitled, "Macrophage-associated nitrogen oxides: A role in acquired resistance to infection by Mycobacterium tuberculosis", was approved by the MRC/Glaxo Tuberculosis Research Initiative.

In vitro analysis of the cytotoxic action of human and murine macrophages using standard tissue culture techniques.

8

Stimulation of macrophages using cytokines in the absence and presence of infection by Mycobacterium species.

Determination of the role of pH manipulation on phagolysosomes and resultant effects on cytotoxic nitrogen oxide synthesis as well as on bacteriostasis.

Lecturing to students pursuing the B.Sc (Hon) degree in Medical Biochemistry.

Presentation of my work in international scientific journals as well as at various congresses.

4. SENIOR SCIENTIST, MRC RESEARCH UNIT FOR THE NEUROCHEMISTRY OF

MENTAL DISEASES - DEPARTMENT OF CHEMICAL PATHOLOGY, TYGERBERG

HOSPITAL (April 1989 - December 1993) In focusing on the central nervous system effects of lithium, as well as the medicinal preservative, methylparaben (MPB), analyses and protocols were set up and characterised for specific projects. These studies have resulted in various publications (see Annexure B). I completed my Ph.D Degree during this period.

Purification and analysis of kinetic data of phosphodiesterase (PDE) isozymes and correlation with cyclic AMP metabolism. Studies were performed using lithium and MPB.

Studying the nitric oxide (NO)/l-arginine pathway in the brain utilising nitrate and nitrite analysis and cGMP radioimmuno-assay.

Investigation into the involvement of excitatory amino acids and free radical mechanisms in the observed effects of lithium.

Investigation into the involvement of adrenergic-cholinergic balance and resultant effects on cyclic nucleotides in the actions of lithium.

Examining the possible role of arachidonic acid metabolites, vitamin E and membrane stability in the subcellular effects of lithium.

Measurement of the oxidative activity of prostaglandin (PG) H2-synthase and investigating subcellular interactions between the oxidative products of the arachidonic acid cascade and the L-arginine: NO pathway.

Investigation into the potential role of NO in neuro-psychiatric illness.

Various aspects of the above work have been presented at national and international congresses.

Participation in clinical ward round in the department of Internal Medicine, Tygerberg Hospital.

5. PHARMACIST, TYGERBERG HOSPITAL (April 1986-March 1989) In addition to normal dispensing duties, I performed the following:

9

Prepared and presented lectures to nursing students (under and post-graduate) at Stellenbosch University.

Attended Professor Raymond Miller‟s workshop on Therapeutic Drug Monitoring at the University of Durban-Westville (June 1988).

Preparation of total parenteral nutrition.

Compounding of ointments, creams and mixtures in bulk and on special requests from various departments.

Drug information regarding the pharmacology, pharmacokinetics, side effects and interactions of drugs to allied health professions.

6. NATIONAL MILITARY SERVICE (SA MEDICAL SERVICES) (JAN 84 - DEC 85)

Medical Officer responsible for pharmaceutical and medical supplies, holding the rank of lieutenant.

Awarded the Propatria medal for active military service in a combat region in 1985.

7. PHARMACIST-INTERN (Jan 83 - Dec 83)

Internship completed in a retail pharmacy (Virginia Pharmacy, Virginia, Freestate).

E) QUALIFICATIONS:

1. PROFESSIONAL QUALIFICATIONS:

Rhodes University 1982 B Pharm

North-West University 1985 Hons B Sc (Pharmacol)

Project: "A double blind comparative study of aspirin, piroxicam and ibuprofen in acute skeletal muscle trauma." - Results on file at The Boots Company Ltd.

Stellenbosch University 1988 M Sc (Pharmacol) cum laude

Thesis: "Studies on subcellular second messenger modulation by lithium"

Stellenbosch University 1992 Ph.D (Neurochem)

Thesis: "Lithium mode of action: A role for cyclic nucleotides and nitric oxide" Doctoral and pre-doctoral research was conducted in the fields of neurophar-

macology, neuropathology and neuropsychiatric disorders.

2. COMPUTER LITERACY:

I am fully computer literate, and conversant in the following: MS Word MS Powerpoint MS Excel GraphPad Prism Use of the Internet (Internet Explorer, Firefox etc)

10

Groupwise

11

ANNEXURE A:

CONGRESS PRESENTATIONS

a) NATIONAL CONFERENCES 1. First Pathology Day Congress, April 1988, Tygerberg Hospital. “Guanyl nucleotide

second messenger modulation by lithium”. Harvey, BH., Carstens, ME. and Taljaard, JJF.

2. South African Association of Hospital and Institutional Pharmacists (SAAHIP)

National Congress, March 1989, Rustenburg. “A double blind comparative study of

aspirin, piroxicam and ibuprofen in acute skeletal muscle trauma”. Harvey, BH. 3. South African Pharmacological Society (SAPS) Congress, October 1989,

Stellenbosch. “Lithium action in bipolar affective disorder : Evidence of the Yin-yang

hypothesis”. Harvey, BH., Carstens, ME. and Taljaard, JJF. 4. South African Association of Hospital and Institutional Pharmacist (SAAHIP) National

Congress, March 1990, Mont-aux-Sources. “Lithium, a key to psychotropic drug

development”. Harvey, BH., Carstens, ME. and Taljaard, JJF. 5. South African Neuroscience Group Symposium, October 1990, Johannesburg. “A free

radical-cyclic GMP link in lithium action - Does lithium stimulate a brain relaxant

factor?” Harvey, BH., Carstens, ME. and Taljaard, JJF. 6. 32nd Annual Pathology Congress, June 1992, Durban. “The stimulating effect of

chronic lithium treatment on basal thyrotropin secretion in rats: in vivo antagonism by

methylparaben”. Jaffer, A., Harvey, BH., Russell, VA., Carstens, ME., de Villiers, AS., Taljaard, JJF.

7. South African Neuroscience Group Symposium, April 1993, Cape Town. “Lithium

promotes cGMP production in the rat brain via a mechanism involving the L-

arginine:nitric oxide pathway: Therapeutic and toxicological implications.” Harvey,

BH., Carstens, ME. and Taljaard, JJF. 8. South African Academy of Pharmaceutical Sciences, June 1993, Durban. “Central

nervous system effects induced by the preservative, methylparaben.” Harvey, BH., Carstens, ME. and Taljaard, JJF.

9. South African Academy of Pharmaceutical Sciences, June 1994, Grahamstown.

“Excitatory amino acids and reactive nitrogen intermediates in the pharmacology of

lithium.” Harvey, BH., Carstens, ME. and Taljaard, JJF. 10. 9th National Psychiatry Congress: Psychiatry 2000, October 1996, The Lost City.

“Toward a neurochemical basis for relapse and refractoriness in affective disorders: A

role for nitric oxide.” Harvey, BH. 11. 10th National Psychiatry Congress, September 1998, Helderfontein Estate,

“Entrenched selective mutism and response to adjunctive treatment with fluoxetine”.

Harvey, BH, Milne M.

12

12. 32nd South African Pharmacology Society Congress, on board the MV Symphony, October 1998, “Neuropharmacology of paradoxical weight gain with selective

serotonin re-uptake inhibitors”. Harvey, BH, Bouwer, CD. 13. Congress of the Biological Psychiatry Group of South Africa, Spier Estate,

Stellenbosch, 26-28 May 1999. “New generation antipsychotics: Integrating the

pharmacology and neuropathology of schizophrenia.” Harvey BH 14. 33rd South African Pharmacology Society Congress, 3-6 October, 1999, President

Hotel, Cape Town. “An investigation into the putative role of nitric oxide in haloperidol-

induced extrapyramidal motor dysfunction”. Bester A, Rheeders, M, Harvey BH. 15. 33rd South African Pharmacology Society Congress, 3-6 October, 1999, President

Hotel, Cape Town. “Chronic myo-inositol attenuates MK801- and d-amphetamine-

induced locomotor behaviour in guinea pigs”. Scheepers AS, Stein DJ, Harvey BH. 16. 34th South African Pharmacology Society and Neurosciences Society Congress, 20-

23 September, 2000, Riverside Conference Center, Durban. “Post-withdrawal nitric oxide-cGMP suppression after long-term haloperidol treatment and effects of

methylene blue manipulation”. Harvey, BH, Bester A. 17. 34th South African Pharmacology Society and Neurosciences Society Congress, 20-

23 September, 2000, Riverside Conference Center, Durban. “Inositol modulates drug-induced locomotor behavior in the guinea pig: Role of 5HT2-D2 receptor cross-talk”.

Scheepers AS, Brand, L , Stein DJ, Harvey BH.

18. 11th National Psychiatry Congress, 26-29th September 2000, Holiday Inn Crown Plaza, Durban. “Chronic inositol induces 5HT2-D2 receptor cross-talk and modulates drug-induced locomotor behavior in the guinea pig”. Scheepers AS, Brand, L, Stein

DJ, Harvey BH.

19. Combined Neuroscience and Immunopharmacology Congress, 16-20 September 2001, Sun City, South Africa. “Stress and modulation of GABA and glutamate activity in select limbic brain regions following acute imipramine-withdrawal”. Jonker L,

Heenop M, Brand L, Stein DJ, Harvey BH. Winner of the South African

Pharmacology Society “Young Scientists Award, 2001” for the best podium

presentation by an M.Sc student (L Jonker). 20. Combined Neuroscience and Immunopharmacology Congress, 16-20 September

2001, Sun City, South Africa. “Pharmacological manipulation of serotonin 5HT2 receptor-mediated locomotor behavior”. Human R, Heenop M, Brand L, Stein DJ,

Harvey BH. 21. Third International Conference on Pharmaceutical and Pharmacological Sciences, 22-

25 September 2002, Boksburg, Gauteng, South Africa. “The role of aging and nitric oxide in neuroleptic-induced tardive dyskinesia: Comparison between haloperidol and

olanzapine”. A Nel, F Oosthuizen, S Niewoudt and BH Harvey. 22. Third International Conference on Pharmaceutical and Pharmacological Sciences, 22-

25 September 2002, Boksburg, Gauteng, South Africa. “Severe stress evokes cognitive dysfunction and aversive behavior in rodents, and is modified by

ketoconazole and serotonin-active drugs”. C Naciti, L Brand, DJ Stein, BH Harvey.

13

Winner of the South African Pharmacology Society “Young Scientists Award,

2002” for the best podium presentation by an M.Sc student (C Naciti). 23. Third International Conference on Pharmaceutical and Pharmacological Sciences, 22-

25 September 2002, Boksburg, Gauteng, South Africa. “The modulating effects of myo-inositol and fluoxetine pre-treatment on muscarinic receptor function in human neuroblastoma cells are dependent upon the phosphoinositde signal transduction

pathway”. Viljoen SL, Brink CB, Harvey BH. 24. Third International Conference on Pharmaceutical and Pharmacological Sciences, 22-

25 September 2002, Boksburg, Gauteng, South Africa. “Behavioral, endocrine and pharmacological validation of a putative animal model of post traumatic stress

disorder (PTSD)”. Oosthuizen F, Naciti C, Brand L, Harvey BH. 25. 12th National Psychiatry Congress, 24-27 September 2002, Somerset West, Western

Cape, South Africa. “Stress, depression and neurodegenerative pathology: New clues

to treatment?” Harvey BH, Stein DJ. 26. Third International Conference on Pharmaceutical and Pharmacological Sciences, 22-

25 September 2002, Boksburg, Gauteng, South Africa. “Evaluation of a possible role

for nitric oxide in post-traumatic stress disorder”. Oosthuizen F, Brand L, Harvey BH. 27. Third International Conference on Pharmaceutical and Pharmacological Sciences, 22-

25 September 2002, Boksburg, Gauteng, South Africa. “Neurobiology of antidepressant withdrawal: Implications for the longitudinal outcome of depression”.

Harvey BH, Stein DJ. 28. Psychopharmacology Congress, 10-13 September 2003, Stellenbosch, South Africa.

“Elevated myo-inositol concentrations down-regulates and desensitizes neuronal

muscarinic receptors”. Brink CB, Viljoen SL, Stein DJ, Harvey BH. 29. 35th South African Pharmacology Society Congress, 14th - 17th September 2003, Cape

Town, South Africa. “Serotonin and stress: Protective or malevolent actions in the bio-

behavioral response to repeated stress?”. Naciti C, Brand L, Stein DJ, Harvey, BH. 30. 35th South African Pharmacology Society Congress, 14th - 17th September 2003,

Cape Town, South Africa. “Neuroleptic-induced dyskinesia is reversed by NO synthase inhibitors and the neurosteroid, dihydroepiandrosterone: Implications for

pathology and treatment”. Nel A, Harvey, BH. 31. 35th South African Pharmacology Society Congress, 14th - 17th September 2003, Cape

Town, South Africa. “Development and application of an analytical method for assessing genetic CYP2D6 and CYP3A4 enzyme polymorphisms”. Mgwabi M, Goosen TC,

Harvey, BH. Runner up for the South African Pharmacology Society “Young

Scientists Award, 2003” for the best podium presentation by an M.Sc student (M

Mgwabi). 32. 35th South African Pharmacology Society Congress, 14th - 17th September 2003, Cape

Town, South Africa. “The antidepressant fluoxetine and myo-inositol inhibit 5HT2A receptor signaling through Gq, whereas imipramine sensitizes signaling”. De Kock SE,

Brink CB, Harvey, BH. Winner of the South African Pharmacology Society “Young

14

Scientists Award, 2003” for the best podium presentation by an M.Sc student (SE

de Kock). 33. 38th South African Pharmacology Congress, held at Bloemfontein, South Africa, 24-27

October 2004. “Loss of antidepressant efficacy after imipramine discontinuation is associated with nitric oxide synthase (NOS) activation”. R Retief, A Nel, G Wegener and B.H. Harvey.

34. 38th South African Pharmacology Congress, held at Bloemfontein, South Africa, 24-27

October 2004. “Nitric oxide involvement in an animal model of post-traumatic stress

disorder (PTSD)”. T Bothma, A Nel, D.J. Stein, G Wegener and B.H. Harvey. Runner

up for the South African Pharmacology Society “Young Scientists Award, 2004”

for the best podium presentation by an M.Sc student (T Bothma). 35. 38th South African Pharmacology Congress, held at Bloemfontein, South Africa, 24-27

October 2004. “The modulating effect of sildenafil pre-treatment on muscarinic acetylcholine and serotonergic 5HT2A receptor function and expression in cell cultures”. Eagar, B.E., Brink, C.B., & Harvey, B.H.

36. 38th South African Pharmacology Congress, held at Bloemfontein, South Africa, 24-27

October 2004. “Characterization of the a2A-lytic effects of mirtazapine and its effects on muscarinic acetylcholine and ß-adrenergic receptor functions”. Khoza, K, Brink, C.B., & Harvey, B.H.

37. 38th South African Pharmacology Congress, held at Bloemfontein, South Africa, 24-27

October 2004.Characterization of the situational reminder in the rodent Time Dependent Sensitization (TDS) Model of Post Traumatic Stress Disorder. ZI Jeeva, Brand L,

Harvey BH. Winner of the South African Pharmacology Society “Young Scientists

Award, 2004” for the best podium presentation by an M.Sc student (ZI Jeeva). 38. 38th South African Pharmacology Congress, held at Bloemfontein, South Africa, 24-27

October 2004. Validation of a modified method for the analysis of corticosterone in rat serum by high-performance liquid chromatography, Viljoen, FP, Brand L, Harvey BH.

39. 39th South African Pharmacology Congress, held at Cape Town, South Africa, 14th-16

September 2005. The relationship between GABA levels and anxiety as determined by an animal model of posttraumatic stress disorder. Myburgh J, Brand L, Rheeders M, Harvey BH.

40. 39th South African Pharmacology Congress, held at Cape Town, South Africa, 14th-16

September 2005. The modulating effects of myo-inositol and prototypical antidepressants on markers of cellular resilience in cultured human neuroblastoma cells. Grobler I, Brink CB, Harvey BH.

41. 39th South African Pharmacology Congress, held at Cape Town, South Africa, 14th-16

September 2005. Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation. Role of 5HT2A/C receptors. Harvey BH.

42. 39th South African Pharmacology Congress, held at Cape Town, South Africa, 14th-16 September 2005. The effects of stress on components of cellular resilience in an animal model of posttraumatic stress disorder (PTSD). A. Korff, DJ Stein, B.H. Harvey.

15

43. 39th South African Pharmacology Congress, held at Cape Town, South Africa, 14th-16 September 2005. The effects of pharmacological treatment on stereotypic behaviour and key parameters in a putative animal model of OCD. S. Korff, DJ Stein, B.H. Harvey.

44. 14th Congress of the South African Society of Psychiatrists (SASOP), 10-14 September

2006, Royal Swazi Sun, Swaziland. Plenary speaker. Investigating the role of the glutamate-nitric oxide pathway in post traumatic stress disorder: Studies using time-dependent sensitisation. Harvey BH.

45. Fourth International Conference on Pharmaceutical and Pharmacological Sciences, 20-

23 September 2006, Vanderbijlpark, Gauteng, South Africa Plenary speaker. “Aripiprazole: Role of partial agonism and its relevance in psychiatry”. Harvey BH.

46. Fourth International Conference on Pharmaceutical and Pharmacological Sciences, 20-

23 September 2006, Vanderbijlpark, Gauteng, South Africa. “The antioxidant, N-acetyl cysteine (NAC), increases vacuous chewing movements in rats: Evidence for striatal oxidative stress”. C Joubert and BH Harvey.

47. Fourth International Conference on Pharmaceutical and Pharmacological Sciences, 20-

23 September 2006, Vanderbijlpark, Gauteng, South Africa. “Muscarinic cholinergic inhibition unmasks antidepressant-like properties of sildenafil: Behavioural and neuroreceptor evidence. H Clapton, CB Brink, BH Harvey.

48. Fourth International Conference on Pharmaceutical and Pharmacological Sciences, 20-

23 September 2006, Vanderbijlpark, Gauteng, South Africa. “The alpha2-lytic properties of mirtazapine is not important for its putative earlier onset of action.” N Liebenberg, CB. Brink, BH Harvey.

49. Fourth International Conference on Pharmaceutical and Pharmacological Sciences, 20-

23 September 2006, Vanderbijlpark, Gauteng, South Africa. “Cortical/hippocampal M1 receptor changes and acoustic startle response in an animal model of posttraumatic

stress disorder”. I Groenewald, L Brand, DJ Stein, BH Harvey. 2nd prize for the South

African Pharmacology Society “Young Scientists Award, 2006” for the best

podium presentation by an M.Sc student (I Groenewald). 50. Fourth International Conference on Pharmaceutical and Pharmacological Sciences, 20-

23 September 2006, Vanderbijlpark, Gauteng, South Africa. “The effects of pharmacological treatment on stereotypic behaviour and key biochemical parameters in a putative animal model of OCD”. S Korff, FH van Der Westhuizen, DJ Stein, BH Harvey.

51. Bristol Myers Squibb SA launch of Abilify (Aripiprazole), a new antipsychotic agent, 24th March 2006, Gallagher Estate, Johannesburg. Plenary speaker. “Aripiprazole: Role of partial agonism and its relevance in psychiatry”. BH Harvey.

52. Biological Psychiatry Congress, 25-28 February 2007, Lord Charles Hotel, Somerset

West, Cape Town, South Africa. Plenary speaker. Reactive nitrogen and oxygen intermediates and oxidative stress in neuroleptic-induced tardive dyskinesia: Implications for prevention and treatment. Harvey BH.

53. Biological Psychiatry Congress, 25-28 February 2007, Lord Charles Hotel, Somerset

West, Cape Town, South Africa. Mechanisms Regulating Onset of Action of Anti-

16

depressants: Novel Perspectives from Pre-Clinical Behavioural and Neuroreceptor Studies. Brink CB, Harvey BH.

54. South African Pharmacology and Toxicology Congress, 2-5 October 2007, Buffelspoort,

South Africa. Reactive nitrogen and oxygen intermediates and oxidative stress in neuroleptic-induced tardive dyskinesia. Harvey BH.

55. South African Pharmacology and Toxicology Congress, 2-5 October 2007, Buffelspoort,

South Africa. Behavioural and pharmacological evaluation of social isolation rearing in

rats: Relevance for schizophrenia. Toua C, Brand L, Harvey BH. Winner of the South

African Pharmacology Society “Young Scientists Award, 2007” for the best

podium presentation by an M.Sc student (C Toua). 56. South African Pharmacology and Toxicology Congress, 2-5 October 2007, Buffelspoort,

South Africa. The modulating effects of selected antidepressants and related drugs on markers of cellular resilience in cultured human neuroblastoma cells. Potgieter L, Brink, CB. Harvey BH.

57. South African Pharmacology Congress, 5-8 October 2008, Grahamstown, South Africa. Regional nitrogen oxides (NOx) and cGMP levels in a rodent model of depression - the Flinders Sensitive Line rat. EL Minnaar, L Brand, PJ van Zyl and BH Harvey. 58. South African Pharmacology Congress, 5-8 October 2008, Grahamstown, South Africa. Regional NMDA receptor binding and acetylcholine levels in a rodent model of depression - the Flinders Sensitive Line rat. PJ van Zyl, L Brand, EL Minnaar, and BH Harvey 59. South African Pharmacology Congress, 5-8 October 2008, Grahamstown, South Africa. Antidepressant-like Properties of sildenafil in a genetic rat model of depression: Role of cholinergic-cGMP interactions in improving antidepressant response. N Liebenberg, L Brand, CB Brink, and BH Harvey 60. Fifth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 23-26 September 2009, Potchefstroom, North-West Province, South Africa. The effect of isolation rearing on schizophrenia-like behaviours and corticostriatal parameters of oxidative stress in rats, and response to clozapine. Moller M, du Preez JL, Emsley RA, Harvey BH. 61. Fifth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 23-26 September 2009, Potchefstroom, North-West Province, South Africa. The structure activity relationship of methylene blue and its analogues as lead compounds for novel antidepressant drug development. Duvenhage I, Petzer JP, Wegener G, Malan SF, Harvey BH. 62. Fifth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 23-26 September 2009, Potchefstroom, North-West Province, South Africa. Stereotypy in the deer mouse, correlation with cortico-striatal oxidative stress and dopamine turnover, and response to combined fluoxetine/risperidone treatment.

Guldenpfennig M, du Preez JL, Wolmarans D, Stein DJ, Harvey BH. Winner of the South

African Society for Basic and Clinical Pharmacology “Young Scientists Award, 2009”

for the best podium presentation by an M.Sc student (M Guldenpfennig). 63. Fifth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 23-26 September 2009, Potchefstroom, North-West Province, South Africa. Basal

17

versus KCl-evoked frontal cortical glutamate release in Flinders Sensitive Line (FSL) and Flinders Resistant Line (FRL) rats: An in vivo microdialysis study. Visser G, Brand L, du Preez JL, Wegener G, Viljoen FP, Harvey BH. 64. Fifth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 23-26 September 2009, Potchefstroom, North-West Province, South Africa. Time-dependent sensitization as a behavioral model for investigating the neurobiology of post-traumatic stress disorder. Harvey BH. 65.South African Biological Psychiatry Congress, Arabella, Western Cape, South Africa, 28-31 May 2009. Cholinergic, GABA and glutamate-nitric oxide signalling in a genetic rodent model of depression, the Flinders Line Sensitive (FSL) rat. Brand L, Minnaar EL,

van Zyl J, Harvey BH. Best poster award 66. South African Biological Psychiatry Congress, Arabella, Western Cape, South Africa, 28-31 May 2009. Animal models of depression: Foolish reductionism of reliable science ? Brink CB, Brand L, Harvey BH 67. South African Biological Psychiatry Congress, Arabella, Western Cape, South Africa, 28-31 May 2009. Invited plenary speaker. Major depression and metabolic encephalopathy: Syndromes more alike than not? Harvey BH 68. South African Biological Psychiatry Congress, Arabella, Western Cape, South Africa, 28-31 May 2009. Increased glutamate NMDA-nitric oxide signaling following stress in the Flinders (FSL/FRL) rat implicates nitric oxide as a vulnerability factor in depression. Harvey BH. Wegener G, Bonefeld B, Müller HK, Volke V, Overstreet DH, Elfving B 69. South African Biological Psychiatry Congress, Arabella, Western Cape, South Africa, 28-31 May 2009. Investigating the pro-cognitive actions of the AMPA receptor positive allosteric modulator, Org 26576, during spatial reference memory acquisition and retrieval in rats. Harvey BH, Hamlyn E, Brand L, Shahid M 70. South African Biological Psychiatry Congress, Arabella, Western Cape, South Africa, 28-31 May 2009. Frontal cortical NMDA/D1 receptor binding following isolation rearing in rats, and differential response to sub-chronic clozapine and haloperidol treatment. Harvey BH, Toua C, Brand L, Mőller M, Emsley RA 71. South African Biological Psychiatry Congress, Arabella, Western Cape, South Africa, 28-31 May 2009. Animal models of obsessive compulsive disorder: Where are we and where are we going? Wolmarans D, Stein DJ, Harvey BH. 72. South African Congress for Pharmacology and Toxicology, Cape Town Lodge Hotel, Cape Town, South Africa, 3-6 October 2010. Behavioral and neurochemical evidence for striatal toxicity in rats treated with phenylglyoxylic acid, a metabolite of styrene.

Terre‟Blanche G, Heyer N, Bergh JJ, Mienie LJ, van der Schyff CJ, Harvey BH. Award for

Best Poster. 73. South African Congress for Pharmacology and Toxicology, Cape Town Lodge Hotel, Cape Town, South Africa, 3-6 October 2010. The effects of sildenafil, with and without atropine, on anxiety-like behavior in rats and on the expression of phosphodiesterase type 5 in rat brain. Slabbert FN, Brink CB, Harvey BH.

18

72. South African Congress for Pharmacology and Toxicology, Cape Town Lodge Hotel, Cape Town, South Africa, 3-6 October 2010. Decreased plasma nitrite (NO2-) levels in a genetic rat model of depression, the Flinders Sensitive Line (FSL) rat: A possible biomarker

of depression? Watson M, Brand L, Viljoen FP, Harvey BH. Winner of the South African

Society for Basic and Clinical Pharmacology “Young Scientists Award, 2010” for the

best podium presentation by an M.Sc student (M Watson). 72. South African Congress for Pharmacology and Toxicology, Cape Town Lodge Hotel, Cape Town, South Africa, 3-6 October 2010. Phosphodiesterase type 5 inhibitors as novel antidepressant strategy: A review of the evidence. Brink CB, Harvey BH. 72. South African Congress for Pharmacology and Toxicology, Cape Town Lodge Hotel, Cape Town, South Africa, 3-6 October 2010. Phosphodoesterase type 5 inhibitors enhance DNA repair capacity in neuroblastoma (SH-SY5Y) cells by enhancing cGMP/protein kinase G signaling. Reay R, van Niekerk BPJ, Harvey BH, Brink CB. 73. Sixth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 25-27 September 2011, Coastlands Hotel Umhlanga, Durban. Natural Stereotypy in Deer Mice and its Association With Frontal Cortical and Striatal Serotonin Transporter (SERT) Density. Wolmarans D, Brand L, Stein DJ, Harvey BH. 74. Sixth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 25-27 September 2011, Coastlands Hotel Umhlanga, Durban. An Investigation into the Role of Noradrenergic Receptors in Conditioned Fear: Relevance to Posttraumatic Stress Disorder (PTSD). Erasmus M, Harvey BH. 75. Sixth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 25-27 September 2011, Coastlands Hotel Umhlanga, Durban. Role of the Peroxisome Proliferator Activated Receptor (PPAR)-γ Pathway in Mood Regulation and Antidepressant Action. Brand SJ, Brink CB, Wegener G, Harvey BH. 76. Sixth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 25-27 September 2011, Coastlands Hotel Umhlanga, Durban. Effect of Early-Life Exposure to the Serotonin-Norepinephrine Reuptake Inhibitor, Venlafaxine, on Behaviour in

Adulthood in Stress-Sensitive Rats. Steyn SF, Harvey BH, Brink CB. Winner of the

South African Society for Basic and Clinical Pharmacology “Young Scientist Award,

2011” for the best podium presentation by an M.Sc student (SF Steyn). 77. Sixth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 25-27 September 2011, Coastlands Hotel Umhlanga, Durban. A single analytical method for the determination of tryptophan, and five of its metabolites in rat plasma

Moller M, Du Preez JL, Harvey BH (SASBCP Best Poster Award). 78. Sixth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 25-27 September 2011, Coastlands Hotel Umhlanga, Durban. Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment. Moller M, Du Preez JL, Harvey BH. 79. Sixth International Conference on Pharmaceutical and Pharmacological Sciences ICPPS), 25-27 September 2011, Coastlands Hotel Umhlanga, Durban. Ozone-induced oxidative stress is associated with a depressogenic effect in stress sensitive rats. Mokoena, M, Brink CB, Oliver DW, Harvey BH.

19

80. Biological Psychiatry Congress, 22-25 September 2011, Protea Hotel, Stellenbosch, South Africa. Neurochemical, peripheral and behavioural effects of social isolation rearing in rats: Relevance for schizophrenia. Möller M, Emsley R, Harvey BH. 81. Congress of the South African Society for Basic and Clinical Pharmacology, University of Pretoria, Pretoria, South Africa, 29 Sept-2 October 2012. Effects of early life exposure of metamphetamine on depressive-like behavior in stress-sensitive rats. Swart C, Harvey BH, Stein DJ, Brink CB. 82. Effects of chronic metamphetamine exposure during puberty on late-life social interactive and sensorimotor gating behaviors in social and isolation reared rats. Congress of the South African Society for Basic and Clinical Pharmacology, University of Pretoria, Pretoria, South Africa, 29 Sept-2 October 2012. Strauss L, Brink CB, Stein DJ, Harvey BH,

Recipient of the Best Young Scientist Award (shared with M Moller). 83. Social isolation rearing induces a pro-inflammatory state in rats withy associated deficits in sensorimotor gating, and is reversed by clozapine or N-acetyl cysteine. Congress of the South African Society for Basic and Clinical Pharmacology, University of Pretoria, Pretoria, South Africa, 29 Sept-2 October 2012. Moller, M, du Preez J, Harvey, BH.

Recipient of the Best Young Scientist Award (shared with L Strauss). 84. Depressive symptoms in black South Africans demonstrate gender-based differences in its association with serum levels of brain derived neurotrophic factor and markers of metabolic and oxidative stress. Congress of the South African Society for Basic and Clinical Pharmacology, University of Pretoria, Pretoria, South Africa, 29 Sept-2 October 2012. Harvey BH. 85. Changes in prescribed daily dosages of antidepressants in compliant vs. non-compliant patients in a private healthcare setting in South Africa. 2013. Poster presented at the 3's Company Pharmacy Conference, Cape Town, South Africa, 4th October 2013. Slabbert,

FN, Lubbe MS, Harvey BH, Brink CB. South African Society for Basic and Clinical

Pharmacology Best Poster Award in Clinical Pharmacology (N Slabbert). 86. N-acetyl cysteine dose dependently reverses sensory-motor gating deficits and alters cortico-striatal dopamine and serotonergic metabolism in rats exposed to social isolation rearing. Poster presented at the 3's Company Pharmacy Conference, Cape Town, South Africa,4th October 2013. Möller M, Du Preez JL, Viljoen FP, Berk M, Emsley R, Harvey BH. 87. Antidepressant properties of azure B and a synthetic analogue of methylene blue. The 3's Company Pharmacy Conference, Cape Town, South Africa,4th October 2013. Delport,

A, Petzer, JP, Harvey BH. Winner of the Academy of Pharmaceutical Sciences Best

Young Scientist Award (A Delport). 88. The effect of early-life exposure of rats to venlafaxine on behavior and neurobiological

markers of antidepressant action in adulthood. The 3's Company Pharmacy Conference,

Cape Town, South Africa, 4th October 2013. Kruger, R, Harvey BH, Brink CB. Winner of

the South African Society for Basic and Clinical Pharmacology “Young Scientist

Award, 2013” (R Kruger).

89. Inflammation as a contributing factor in the pathophysiology of schizophrenia: pre-

clinical and clinical evidence. The 3's Company Pharmacy Conference, Cape Town, South

Africa, 4th October 2013. Moller M, Harvey BH.

20

b) INTERNATIONAL CONFERENCES

1. 3rd Society of Neurosciences of Africa (SONA) International Conference, April 21 - 25

1997, Cape Town. “Glutamatergic mechanisms in affective disorders and a role for

nitric oxide.” Harvey, BH. 2. Lithium-SA, International Conference on the Biological Effects of Lithium, 1-6

September 1997, Kruger National Park. “Glutamate and nitric oxide mechanisms in

lithium-associated relapse and refractoriness.” Harvey, BH. 3. 9th Biennial Meeting of the International Society for Comparative Psychology, 15

September 1998, Cape Town, South Africa. “Fluoxetine decreases stereotyped

behavior in primates”. Hugo C, Seier J, Mdhuli C, Daniels W, Harvey B , Du Toit DF, Wolfe-Coote S, Stein DJ.

4. Lithium-Lexington, 1999; Lithium in Clinical Medicine and Research: 50th Anniversary

Congress, 7-11 May 1999, University of Kentucky, Lexington, USA. “The haemopoietic and immuno-modulating action of lithium-salts: An investigation into the

chemotherapy of HIV infection in South Africa.” Harvey BH, Meyer CL, Gallicchio VS. 5. Congress of the Collegium Internationale Neuro-psychopharmacologicum (CINP),

Brussels, Belgium, 9-13 July 2000. “Chronic inositol modulates 5HT2 and D2 receptor function in the guinea pig striatum: A behavioral study towards a therapeutic role in

OCD”. Harvey BH, Scheepers A, Brand L, Stein DJ. Recipient of a “CINP Poster

Award”. 6. Federation of European Neuroscience Societies (FENS) 2000 Congress, Brighton,

United Kingdom, 20-24 June 2000. “Chronic haloperidol-induced vacous chewing movements are linked to suppression of striatal cyclic GMP: Exacerbation by early

methylene blue administration.” Harvey BH, Bester A. Recipient of an International

Brain Research Organisation (IBRO) International Travel Award. 7. International Immunopharmacology Congress, 16-20 September 2001, Sun City,

South Africa. “Retroviral infection and effects on macrophage lineage derived cells of

bone marrow and brain and their response to lithium.” Meyer CL, Mampuru L, Harvey

BH, Becker RS, Manji HK, Gallicchio VS. 8. Congress of the Collegium Internationale Neuro-psychopharmacologicum (CINP),

Montreal, Canada, 23-28 June 2002. “Elevated myo-inositol concentrations suppress neuronal muscarinic receptor number and function” Brink CB, Viljoen SL, Stein DJ,

Harvey BH. 9. Congress of the Collegium Internationale Neuro-psychopharmacologicum (CINP),

Montreal, Canada, 23-28 June 2002. “Dizocilpine reverses withdrawal associated effects on swim stress and hippocampal GABA-glutamate function after

chronic imipramine treatment”. Harvey BH, Jonker LP, Brand L, Heenop M, Stein DJ. 10. World Congress of Pharmacology, San Francisco, USA, 7-12 July 2002.

“Antidepressant withdrawal evokes stress and limbic GABA/glutamate dysfunction.

21

Role of glutamate and nitric oxide”. Harvey BH, Jonker LP, Brand L, Heenop M.

Recipient of an International Union of Pharmacology (IUPHAR) Travel Award. 11. 6th International Brain Research Organisation World Congress of Neuroscience,

Prague, Czech Republic, 10-15 July 2003. ”Sustained effects of a stress-restress paradigm on nitric oxide synthase activity, GABA levels and NMDA receptors in the

rat hippocampus.” BH Harvey, Oosthuizen F, Brand L, DJ Stein. 12. 34th International Society for Psychoneuroendocrinology Conference, New York, USA,

7-9 September 2003. ”Cognitive and hippocampal/cortical 5HT1A/2A-receptor changes evoked by a stress-restress paradigm are modulated by ketoconazole and

serotonergic-active drugs.” Harvey BH, Naciti C, Brand L, Stein DJ.

13. 24th Collegium Internasionale Neuropsychopharmacologicum (CINP) Congress, Paris, France, June 20-24, 2004. Cognitive dysfunction and serotonin receptor changes evoked by stress-restress are reversed by the steroid synthesis inhibitor,

ketoconazole. Brand L, Naciti C, Stein DJ, Harvey BH.

14. 24th Collegium Internasionale Neuropsychopharmacologicum (CINP) Congress, Paris, France, June 20-24, 2004. The alpha-2-lytic action of mirtazapine and its effects on adenyl cyclase activity and on muscarinic acetylcholine receptor function. Brink CB,

Khoza K, Stein DJ, Harvey BH.

15. 24th Collegium Internasionale Neuropsychopharmacologicum (CINP) Congress, Paris,

France, June 20-24, 2004, plenary speaker. The neurobiology of antidepressant

withdrawal: linking compliance to treatment response or relapse. Harvey BH.

16. 24th Collegium Internasionale Neuropsychopharmacologicum (CINP) Congress, Paris, France, June 20-24, 2004. Regional examination of the brain nitric oxide system in the Flinders Sensitive Line rat, a genetic animal model of depression. Bonefeld, BE, Volke

V, Harvey BH, Overstreet DH, Rosenberg R, Wegener G.

17. 24th Collegium Internasionale Neuropsychopharmacologicum (CINP) Congress, Paris, France, June 20-24, 2004. Chronic treatment with citalopram and augmentation with lithium does not modify the regional neurochemistry of nitric oxide in rat brain.

Wegener G, Bandbey Z, Heiberg IL, Volke V, Trabace L, Harvey BH.

18. 54th Czech and Slovak Annual Convention of Pharmacology, Ceské Budejovice, Czech Republic, 8-10 September 2004. Muscarinic acetylcholine receptor modulatory

properties of sildenafil. Brink C.B., Eagar B.E. & Harvey B.H. 19. Regional International Brain Research Organization (IBRO) and Collegium

Internasionale Neuropsychopharmacologicum (CINP) Congress, Cape Town, South Africa, 19-21 April 2005. Nitric oxide in an animal model of posttraumatic disorder.

Harvey BH, Bothma, Wegener G, Stein DJ. 20. Regional International Brain Research Organization (IBRO) and Collegium

Internasionale Neuropsychopharmacologicum (CINP) Congress, Cape Town, South Africa, 19-21 April 2005. Trauma and re-experience evoke anxiety but different neuro-

endocrine responses. Jeeva Z, Brand L, Stein DJ, Harvey BH.

22

21. 8th World Congress of Biological Psychiatry, 28 June–3 July 2005, Vienna, Austria.

Imipramine withdrawal activates NOS through 5HT2A/C receptors. Harvey BH, Retief R, Wegener G.

22. European Neuropsychopharmacology Congress, 22-26 October 2005, Amsterdam,

The Netherlands. Early adverse experience decreases glucocorticoid receptor immunoreactivity in the dentate gyrus following adulthood re-stress and is reversed by

escitalopram pre-treatment. Uys JDK, Muller CJF, Marais L, Harvey BH, Stein DJ, Daniels WMU.

23. 15th World Congress of Pharmacology (IUPHAR), 2-7 July 2006, Beijing, China.

Diverse monoamine-HPA-axis changes and anxiety after stress and re-stress in an

animal model of post traumatic stress disorder. Harvey BH, Brand L, Jeeva, Z, Stein DJ.

24. 15th World Congress of Pharmacology (IUPHAR), 2-7 July 2006, Beijing, China.. The

pharmacokinetic – pharmacodynamic (PK/PD) relationship of diazepam in rats with

anxiety after exposure to repeated stress. M Rheeders, L Brand, J Myburgh and BH

Harvey. 25. 15th World Congress of Pharmacology (IUPHAR), 2-7 July 2006, Beijing, China.

GABA levels in the hippocampus and frontal cortex of rats following stress and -re-

stress in an animal model of PTSD. L Brand, J Myburgh, M Rheeders and BH

Harvey. 26. 25th Collegium Internasionale Neuropsychopharmacologicum (CINP) Congress,

Chicago, USA, J9-13th July 2006. Effects of stress and re-stress on corticosterone, regional brain monoamines and anxiety in an animal model of post traumatic stress

disorder (PTSD). Harvey BH, Brand L, Jeeva, Z, Stein DJ. 27. 25th Collegium Internasionale Neuropsychopharmacologicum (CINP) Congress,

Chicago, USA, 9-13 July 2006. Plenary speaker and session chair. Involvement of nitric oxide in post traumatic stress disorder (PTSD): Evidence from an animal model.

Harvey BH. 28. 25th Collegium Internasionale Neuropsychopharmacologicum (CINP) Congress,

Chicago, USA, J9-13th July 2006. Nitric oxide pathways in anxiety and stress-related disorders: From gene to patient. Wegener G, Volke V, Buttenschon H, Mors O,

Harvey BH. 29. 25th Collegium Internasionale Neuropsychopharmacologicum (CINP) Congress,

Chicago, USA, J9-13th July 2006. Modulation of neurotoxicity by myo-inositol and

prototype antidepressants in human neuroblastoma cells. Brink CB, Grobler I, Harvey

BH. 30. McMaster University, Department of Psychiatry & Behavioural Neurosciences, Mood

Disorders Program Academic Day, Hamilton, Ont, Canada. July 13 2006. Plenary

speaker. "Adaptive plasticity during stress and depression: A new challenge for

psychopharmacology". BH Harvey.

23

31. Bioscience Congress 2006, Glasgow, Scotland, 23-27 July 2006. “The effects of pharmacological treatment on stereotypic behavior and key biochemical parameters in

a putative animal model of OCD”. Korff S, Stein D, Harvey BH 32. European College of Neuropsychopharmacology (ECNP) Congress, Vienna, Austria

13-17th October 2007. The nitric oxide pathway in anxiety and stress-related

disorders. Wegener G, Vistisen AK, Nielsen SR, Volke V, Harvey BH. 33. 10th International Conference on Philosophy, psychiatry and Psychology, 26-30

August, 2007, Sun City, South Africa. Therapeutic advances in depression: Resetting

the Rationale. Harvey BH (invited plenary speaker). 34. 49th Scandanavian College of Neuropsychopharmacology Congress, Juan-les-Pins,

France, April 2-4, 2008. Stress associated changes in the nitric oxide signalling

cascade. Wegener G, Bonefeld B, Muller H, Volke V, Overstreet DH, Harvey BH, Elving B.

35. 26th College Internasionale Neuropsychpharmacologicum Congress, Munich,

Germany, 13-17th July 2008. Antidepressant-like Properties of Sildenafil in a Genetic

Rat Model of Depression and Effects on Markers of Cellular Resilience. Harvey BH, Liebenberg N, Overstreet DH, Wegener G, Brink CB.

36. 26th College Internasionale Neuropsychpharmacologicum Congress, Munich,

Germany, 13-17th July 2008. Stress associated changes in the nitric oxide signaling

cascade in a genetic animal model of depression. Wegener G, Harvey BH, Volke V, Bonefeld B, Müller H, Overstreet DH, Elfving B.

37. The IXth World Conference on Clinical Pharmacology and Therapeutics (CPT2008),

Quebec City, Canada, July 27 - August 1, 2008. Conditioned taste aversion in rats following prior exposure to repeated or single prolonged stress. Brand L, Groenewald

I, Harvey BH. 38. The IXth World Conference on Clinical Pharmacology and Therapeutics (CPT2008),

Quebec City, Canada July 27 - August 1, 2008. Diverse classes of antidepressant activate separate neuroprotective mechanisms in cultured human neuroblastoma

cells. Brink CB, Potgieter L, Harvey BH. 39. EPHAR 2008 and the Serotonin Club Satellite Meeting, 13th - 17th July 2008,

Manchester, UK. Cortico-striatal cAMP-PDE4 signaling in stereotypic deer mice and

response to chronic fluoxetine versus desipramine treatment. Harvey BH, Korff S, Stein DJ.

40. European College of Neuropsychopharmacology (ECNP) Congress, Barcelona, Spain

30 August – 3rd September 2008. Isolation rearing-induced cognitive deficits involves

opposing NMDA/D1 receptor changes in rat frontal cortex. Harvey BH, Toua C, Trabace L, Brand L.

41. Danish Society of Biological Psychiatry Symposium on Novel Insights in the

Pathophysiology of Psychiatric Disorders, 12 September 2008, University of Aarhus, Aarhus, Denmark. Non-compliance and inappropriate antidepressant discontinuation

and implications for the neurobiology and longitudinal outcome of depression. BH

Harvey (invited plenary speaker).

24

42. 9th World Congress of Biological Psychiatry, Paris, 28 June – 2 July 2009. Chaired an academic session, entitled “Glutamate as a neurobiological target in anxiety disorders:

Metabotropic or ionotropic receptors?” BH Harvey. 43. 9th World Congress of Biological Psychiatry, 28 June - 2 July 2009, Paris, France.

Stress-associated changes in the nitric oxide signaling cascade in a genetic animal model of depression. Wegener G, Harvey B, Elfing B, Muller H, Volke V.

44. 9th World Congress of Biological Psychiatry, 28 June - 2 July 2009, Paris, France.

Invited to co-chair a “free communication” session on pre-clinical research in anxiety disorders.

45. 41st Brazilian Congress on Pharmacology and Therapeutic Studies. Presenting an

invited plenary talk entitled “Studying the neurobiology of post traumatic stress disorder using time-dependent sensitisation” at a symposium on “New Developments in PTSD”, Ribeirao Preto Convention Center, Ribeirao Preto, Sao Paulo, Brazil, 17-20 October 2009.

46. Poster presentation at the 3rd International Symposium on Physiology and

Pharmacology of Temperature Regulation (PPTR) held in Matsue, Japan, from July 23 (Thu) to 26 (Sun), 2009, entitled “Effects of simulated recurrent mycoplasma infection on fever, growth and learning and memory”, Swanepoel T, Harden LM, Harvey BH, Mitchell D.

47. Poster presentation at the 36th International Congress of the International Union of

Physiological Sciences (IUPS), held in Kyoto, Japan from July 27 to August 1, 2009, entitled “Effects of simulated recurrent mycoplasma infection on fever, growth and learning and memory”, Swanepoel T, Harden LM, Harvey BH, Mitchell D.

48. Invited presentation at a symposium on the Biomedical Pathophysiology Relevant to Stress and Disease, entitled “Possible Resilience and Susceptibility Factors Related to Oxidative Stress and the Development of Depression in Male and Female Black

Africans: The SABPA study. Harvey BH, Malan L, Hamer, M, Potgieter JC, Schutte AE, Schutte R, Huisman HW, Van Rooyen JM, Fourie CMT. 68th Annual meeting of the American Psychosomatic Society, Maritime Hotel, Portland, Oregon, USA. 11-13 March 2010.

49. Invited research report presented at the Agomelatine Master Class Symposium hosted by Servier Pharmaceuticals, 10-13th February 2010, Paris, France, entitled

“Antidepressant discontinuation and the benefits of agomelatine”. Harvey BH.

50. 27th College Internasionale Neuropsychopharmacologicum Congress, Hong Kong, China, 06-10 June 2010. Monoamine oxidase-A inhibition by methylene blue and

selected analogues and antidepressant effects in the rat forced swim test. Harvey BH, Duvenhage I, Petzer JP, Malan SF, Wegener G.

51. International Anxiety Disorders Symposium, Spier Estate, Cape Town, South Africa, 1-2

May 2010. Stereotypy in the deer mouse: Correlation with cortico-striatal oxidative status and dopamine turnover, and response to combined fluoxetine/risperidone

treatment. Güldenpfennig M, du Preez JL, Wolmarans D, Stein DJ, Harvey BH. Best

Poster Award.

25

52. International Union of Pharmacology World Pharma Congress, Copenhagen, Denmark,

17-23 July 2010. Cholinergic and glutamate-nitric oxide signaling pathways in a genetic animal model of depression, the Flinders Sensitive Line (FSL) rat. Brand L, Minnaar EL,

van Zyl J, Wegener G, Harvey BH.

53. 10th World Congress of Biological Psychiatry, 29 May – 2 June 2011, Prague, Czech Republic. Endogenous markers of nitric oxide in plasma of the Flinders sensitive line (FSL) rat, a genetic animal model of depression. Brand L, Watson M, Viljoen FP,

Harvey BH.

54. Anxiety and Depression: 21st Neuropharmacology Conference, 10-11 November 2011, Westin Tyson‟s Corner, Tyson‟s Corner, Virginia, USA (Satellite meeting of the 2011 Society for Neuroscience Congress, Washington, USA). Isolation Rearing Alters Plasma Tryptophan Metabolism in Rats and Decreases the Neuroprotective Ratio: Reversal by

Clozapine. Moller M, Du Preez JL, Harvey BH.

55. 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy. Social isolation rearing in rats induces schizophrenia-like behaviours that are reversed by sub-chronic treatment with clozapine or N-acetyl cycteine. Moller M,

Emsley. R, Harvey BH.

56. 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy. Social isolation rearing in rats alters plasma tryptophan metabolism and

is reversed by sub-chronic clozapine treatment. Moller M, Du Preez JL, Harvey BH.

57. African Congress of Pharmacology, La Palm Hotel, Accra, Ghana, 11-13th July 2012.

Invited plenary speaker. Using animal models to advance our understanding of anxiety

and stress-related disorders. Harvey BH.

58. African Congress of Pharmacology, La Palm Hotel, Accra, Ghana, 11-13th July 2012. Chronic Ozone Exposure Induces Oxidative Stress in Stress-sensitive Rats: Association with Memory Impairment and Depressogenic and Anxiogenic Effects. Mokoena M, Brink

CB, Oliver DW, Harvey BH.

59. Experimental Biology Congress 2013, Boston, MA, USA, 20-14 April 2013. Chronic Ozone Exposure Induces Oxidative Stress in Stress-sensitive Rats: Association with Memory Impairment and Depressogenic and Anxiogenic Effects. Mokoena ML, Brink

CB, Oliver DW, Harvey BH.

60. Invited by the organisers of 11th World Congress of Biological Psychiatry, held in Kyoto,

Japan, 23-27 June 20-13, to chair a symposium entitled “Novel approaches for the treatment of unipolar depression”, as well as to present a talk on “N-acetyl cysteine as a novel treatment for depression”.

61. 11th World Congress of Biological Psychiatry, Kyoto, Japan, 23-27 June 20-13. Social isolation rearing induces a pro-inflammatory state in rats with associated mitochondrial, neurochemical and behavioural deficits: Reversal by Clozapine or N-acetylcysteine.

Harvey BH, Möller M, Du Preez JL. 62. 17th World Congress of Basic and Clinical Pharmacology, Cape Town, South Africa, 13-

18 July 2014. The long-lasting effects of early-life administration of methamphetamine

26

on depressive-like behaviour in stress-sensitive rats. Mouton, M., Swart, C, Harvey

B.H., Brink, C.B.

63. 17th World Congress of Basic and Clinical Pharmacology, Cape Town, South Africa, 13-18 July 2014. The antidepressant properties of azure B and ethylthioninium chloride, a

synthetic methylene blue analogue. Delport A, Petzer JP, Petzer A, Harvey BH.

64. 17th World Congress of Basic and Clinical Pharmacology, Cape Town, South Africa, 13-18 July 2014. The selective α2C-antagonist ORM 10921 improves recognition memory and shows modest antipsychotic-like effects in an animal model of schizophrenia.

Erasmus M, Shahid M, Sallinen J, Harvey BH.

65. 17th World Congress of Basic and Clinical Pharmacology, Cape Town, South Africa, 13-

18 July 2014. Invited speaker: Methylene blue: New light through old windows. Harvey

BH.

66. 17th World Congress of Basic and Clinical Pharmacology, Cape Town, South Africa, 13-

18 July 2014. Invited speaker: Behavioural and biological validation of an animal model

of obsessive-compulsive disorder (OCD). Harvey BH.

67. Invited by the organisers of 17th World Congress of Basic and Clinical Pharmacology,

Cape Town, South Africa, 13-18 July 2014 to chair a symposium entitled “The nitric oxide-cGMP pathway in neuropsychiatric illness: An update”.

68. 11th Congress of the International Serotonin Society, Arabella Estate, South Africa, 9-12 July 2014. Social isolation rearing induces elevated tryptophan, anthranilic acid and 3-OH anthranilic acid and altered cortico-striatal serotonin metabolism –relevance for

schizophrenia. Möller M, Du Preez JL, Berk M, Harvey BH.

ANNEXURE B:

PUBLICATIONS BASED ON ORIGINAL RESEARCH

1. Harvey, BH (1989). A double blind, comparative, single centre study of aspirin, piroxicam and ibuprofen in acute musculo-skeletal trauma. South African Journal for Hospital and Institutional Pharmacists (currently a supplement to the South African Pharmaceutical Journal). 14, 32-36.

2. Harvey BH, Carstens ME, Taljaard JJF. (1990). Lithium modulation of cortical cyclic nucleotides: Evidence of the Yin-Yang hypothesis. European Journal of Pharmacology 175, 128-136.

3. Harvey BH, Carstens ME, Taljaard JJF (1990). A novel hypothesis for the psychomodulating effects of lithium: The role of essential fatty acids, eicosanoids and subcellular second messengers. Medical Hypotheses 32, 52-58.

4. Harvey BH, Carstens ME, Taljaard JJF (1990). Antagonism of a novel cholinotropic property of lithium by scopolamine. South African Journal of Science 86, 265-269.

27

5. Harvey BH (1991). Lithium, a drug for all seasons. South African Journal for Hospital and Institutional Pharmacists (currently a supplement to the South African Pharmaceutical Journal) 16, 14-16.

6. Harvey BH, Carstens ME, Taljaard, JJF (1992). Central effects of the preservative, methylparaben: in vivo activation of the cAMP-specific phosphodiesterase and reduction of cAMP. Biochemical Pharmacology 44, 1053-1057.

7. Harvey BH, Carstens ME, Taljaard, JJF (1993). Absence of an effect of the lithium-induced increase in cGMP on the cGMP-stimulated phosphodiesterase (PDE II): Evidence of cAMP-specific hydrolysis Neurochemical Research 18, 1095-1100.

8. Jaffer A, Harvey BH, Russell VA, Carstens ME, de Villiers AS, Taljaard JJF (1993). The stimulating effect of chronic lithium treatment on basal thyrotropin secretion in rats: in vivo antagonism by methylparaben. Neurochemical Research 18, 1057-1061.

9. Harvey BH, Carstens ME, Taljaard JJF (1993). Mechanism of lithium action: Essential fatty acids. Reviews in Contemporary Pharmacotherapy 4, 312-313.

10. Harvey BH (1993). Mechanism of lithium action: Cyclic GMP and cyclic nucleotide balance. Reviews in Contemporary Pharmacotherapy 4, 309-310.

11. Harvey BH, Carstens ME, Taljaard JJF (1994). Evidence that lithium induces a glutamatergic:nitric oxide - mediated response in rat brain. Neurochemical Research 19, 469-474.

12. Harvey BH, Taljaard JJF (1994). Nitric oxide and cyclooxygenase-derived free radicals in the therapeutic and toxic effects of lithium. Lithium 5, 67-72.

13. Harvey BH (1996). Affective disorders and nitric oxide: A role in pathways to relapse and refractoriness. Human Psychopharmacology 11, 309-319.

14. Bouwer CD, Harvey, BH (1996). Phasic craving for carbohydrate observed with citalopram. International Clinical Psychopharmacology 11, 273-278.

15. Harvey BH (1997) The neurobiology and pharmacology of depression: A comparative overview of serotonin-selective anti-depressants. South African Medical Journal 87, 540-552.

16. Harvey BH, Milne M (1998). Pharmacotherapy of selective mutism: Two case studies of severe entrenched mutism responsive to adjunctive treatment with fluoxetine. Southern African Journal of Child and Adolescent Mental Health 10, 59-66.

17. Harvey BH, Stein DJ, Emsley RA (1999). The new-generation anti-psychotics: Integrating the neuro-pathology and pharmacology of schizophrenia. South African Medical Journal 89, 661-672.

18. Stein DJ, Emsley RA, Oosthuizen P, Harvey BH (1999). New developments in schizophrenia research: An overview for the practitioner. South African Journal of Psychiatry 5, 6-8.

28

19. Harvey BH, Bouwer CD (2000). Neuropharmacology of paradoxical weight gain with selective serotonin reuptake inhibitors. Clinical Neuropharmacology 23: 90-97.

20. Harvey BH (2000). Acid-dependent dismutation of nitrogen oxides may be a critical source of nitric oxide in human macrophages. Medical Hypotheses 54: 829-831

21. Harvey BH, Bester A (2000). Withdrawal-associated changes in peripheral nitrogen oxides and striatal cGMP after chronic haloperidol treatment. Behavioral Brain

Research 111: 203-211. South African Academy of Pharmaceutical Sciences

“Best Publication Award in Pharmacology, 2001.

22. Bester A, Harvey BH (2000). Early suppression of striatal cyclic GMP may pre-determine the induction and severity of chronic haloperidol-induced vacous chewing movements. Metabolic Brain Disease 15: 273-283.

23. Seedat S, Stein DJ, Harvey BH (2001). Inositol in the treatment of compulsive skin-picking and trichotillomania. Journal of Clinical Psychiatry 62: 60-61.

24. Harvey BH, Scheepers AS, Brand L, Stein DJ (2001). Chronic inositol increases striatal D2 receptors but does not modify dex-amphetamine-induced motor behavior: Relevance to obsessive compulsive disorder. Pharmacology Biochemistry and

Behavior 68: 245-253. South African Academy of Pharmaceutical Sciences “Best

Publication Award in Pharmacology, 2002.

25. Harvey BH, Brink CB, Seedat S, Stein DJ (2002). Defining the neuro-molecular action of myo-inositol: Application to obsessive-compulsive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26: 21-32.

26. Harvey BH, Meyer CL, Gallicchio VS, Manji HS (2002). Lithium salts in AIDS and AIDS-related dementia. Psychopharmacology Bulletin 36: 5-26.

27. Harvey BH, Jonker LP, Brand L, Heenop M, Stein DJ (2002). NMDA receptor involvement in imipramine withdrawal-associated effects on swim stress, GABA levels

and NMDA receptor binding in rat hippocampus. Life Sciences 71: 43-54. Janssen-

Cilag “Best Publication Award-2003” in the Faculty of Health Sciences, North-

West University.

28. Wegener G, Volke V, Harvey BH, Rosenberg R (2003). Local but not systemic administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Research 959: 128-134.

29. Nel A, Harvey BH (2003). Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: Reversal with olanzapine. Behavioral Pharmacology 14: 251-255.

30. Hugo C, Seier J, Mdhluli C, Daniels W, Harvey BH, Du Toit DF, Wolfe-Coote S, Nel D, Stein DJ (2003). Fluoxetine decreases stereotyped behavior in primates. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27: 639-643.

31. Uys JDK, Stein DJ, Daniels WMU, Harvey BH (2003). Pre-clinical models of anxiety disorders. Current Psychiatry Reports 5: 274-81.

29

32. Harvey BH, Nel A, (2003). Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia. Brain Research Bulletin 61: 407-416.

33. Harvey BH, Naciti C, Brand L, Stein DJ (2003). Endocrine, cognitive and hippocampal/cortical 5HT1A/2A receptor changes evoked by a time dependent

sensitisation (TDS) stress model in rats. Brain Research 983: 97-107. South African

Academy of Pharmaceutical Sciences “Best Publication Award in

Pharmacology, 2004”, as well as the Janssen-Cilag “Best Publication Award-

2004” in the Faculty of Health Sciences, North-West University.

34. Harvey BH, McEwen BS, Stein DJ (2003). Neurobiology of antidepressant withdrawal: Implications for the longitudinal outcome of depression. Biological Psychiatry 54: 1105-1117.

35. Brink CB, Harvey BH, Bodenstein J, Venter DP, Oliver DW (2004). Understanding drug action and therapeutics: Relevance of G-protein-coupled receptors and signal transduction. British Journal of Clinical Pharmacology 57: 373-87.

36. Harvey BH, Oosthuizen F, Brand L, Wegener G, Stein DJ (2004). Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat

hippocampus. Psychopharmacology (Berl.) 175: 494-502. South African

Pharmacology Society “Best Publication Award, 2005.

37. Brink CB, Viljoen L, Stein DJ, Harvey BH (2004). Elevated myo-inositol concentrations down-regulates and desensitizes neuronal muscarinic receptors. Metabolic Brain Disease 19: 51-70.

38. Carey PD, Warwick J, Harvey BH, Stein DJ, Seedat S (2004). Single Photon Emission Computed Tomography in obsessive-compulsive disorder before and after treatment with inositol. Metabolic Brain Disease 19: 125-134.

39. Harvey BH (2004). Lithium: Priming the next 50 years. South African Psychiatry Review 7: 12

40. Wegener G, Bandpey Z, Heiberg IL, Volke V, Trabace L, Harvey BH (2004). Chronic treatment with citalopram and augmentation with lithium does not modify the regional neurochemistry of nitric oxide in rat brain. Journal of Physiology and Pharmacology 55: 575-586.

41. Carey PD, Warwick J, Niehaus DJH, van der Linden G, van Heerden BB, Harvey BH, Seedat S, Stein DJ (2004). Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BioMed Central Psychiatry Oct 14; 4(1): 30.

42. Harvey BH, Naciti C, Brand L, Stein DJ (2004). Serotonin and stress: Protective or malevolent actions in the biobehavioural response to repeated trauma. Annals of the New York Academy of Science 1032: 267-272.

43. Oosthuizen F, Wegener G, Harvey BH (2005). Role of nitric oxide as inflammatory mediator in post-traumatic stress disorder (PTSD): Evidence from an animal model. Neuropsychiatric Disease and Treatment 1: 109-124.

30

44. Harvey BH, Bothma T, Nel A, Wegener G, Stein DJ (2005). Involvement of the NMDA

receptor, NO-cyclic GMP and nuclear factor - in an animal model of repeated

trauma. Human Psychopharmacology 20: 367-73. South African Academy of

Pharmaceutical Sciences “Best Publication Award in Pharmacology, 2006”, and

Janssen-Cilag “Best Publication Award-2005” in the Faculty of Health Sciences,

North-West University

45. Stein DJ, Harvey BH, Uys JD, Daniels WM (2005). Suffer the children: Psychobiology of early adversity. CNS Spectrums 10: 612-5.

46. Brink CB, Harvey BH, Brand L (2006). Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. Recent Patents in CNS Drug Discovery 1: 29-41.

47. Uys JDK, Muller CJF, Marais L, Harvey BH, Stein DJ, Daniels WMU (2006). Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: Reversal by escitalopram. Neuroscience 137: 619-625.

48. Harvey BH, Brand L, Jeeva Z, Stein DJ (2006). Cortical/hippocampal monoamines, HPA-axis changes and aversive behavior following stress and re-stress in an animal model of post traumatic stress disorder. Physiology and Behavior 87: 881-890.

49. Korff S, Harvey BH (2006). Animal models of obsessive compulsive disorder (OCD): Rationale to understanding psychobiology and pharmacology. Psychiatric Clinics of North America 29: 371-390.

50. Harvey BH, Retief R, Nel A, Wegener G (2006). Increased hippocampal NO synthase activity and stress responsiveness after imipramine discontinuation: Role of 5HT2A/C receptors. Metabolic Brain Disease 21: 211-20.

51. Harvey BH (2006). Adaptive plasticity during stress and depression and the role of glutamate-nitric oxide pathways. South African Psychiatry Review 9: 132-139.

52. Brink CB, Clapton JD, Eager BE, Harvey BH (2008). Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade. Evidence from behavioural and neuro-receptor studies. Journal of Neural Transmission 115:

117-25. South African Society for Basic and Clinical Pharmacology “Best

Publication Award, 2009”.

53. Korff S, Stein DJ, Harvey BH (2008). Stereotypic behaviour in the deer mouse: Pharmacological validation and relevance for obsessive compulsive disorder.

Progress in Neuropsychopharmacology and Biological Psychiatry 32: 348-55. South

African Academy of Pharmaceutical Sciences “Best Publication Award in

Pharmacology, 2009”

54. Harvey BH, Joubert C, Du Preez J, Berk M (2008). Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. Neurochemical Research 33: 508-17.

55. Harvey BH (2008). Is major depressive disorder a metabolic encephalopathy? Human Psychopharmacology 23: 371-384.

31

56. Brand L, Groenewald I, Stein DJ, Wegener G, Harvey BH (2008). Stress and re-stress increases conditioned taste aversion learning in rats: Possible frontal cortical and hippocampal muscarinic receptor involvement. European Journal of Pharmacology 586: 205-211.

57. Stein DJ, Daniels WMU, Savitz J, Harvey BH (2008). Brain-derived neurotrophic factor: The neurotrophin hypothesis of psychopathology. CNS Spectrums 13: vol 11 945-949.

58. Korff S, Stein DJ, Harvey BH (2009). Cortico-striatal cyclic AMP-phosphodiesterase-4 signalling and stereotypy in the deer mouse: Attenuation after chronic fluoxetine

treatment. Pharmacology Biochemistry and Behavior 92: 514-520. South African

Academy of Pharmaceutical Sciences “Best Publication Award in

Pharmacology, 2010”

59. Hamlyn E, Brand L, Shahid M, Harvey BH (2009). The ampakine, Org 26576, bolsters early spatial reference memory and retrieval in the 5-day Morris water maze task: A dose-ranging study in rats. Behavioural Pharmacology 20: 662-776.

60. Wegener G, Harvey BH, Bonefeld B, Müller HK, Volke V, Overstreet DH, Elfving B (2010). Stress associated changes in the nitric oxide signaling cascade in a genetic animal model of depression. International Journal of Neuropsychopharmacology 13: 461-73.

61. Toua C, Brand L, Mőller M, Emsley RA, Harvey BH (2010). The effects of sub-chronic clozapine and haloperidol administration on isolation rearing induced changes in frontal

cortical NMDA and D1 receptor binding in rats. Neuroscience 165: 492-9. South

African Academy of Pharmaceutical Sciences “Best Publication Award in

Pharmacology, 2011”

62. Liebenberg N, Wegener G, Harvey BH, Brink CB (2010). Investigating the role of protein kinase-G in the antidepressant-like response of sildenafil in combination with muscarinic acetylcholine receptor antagonism. Behavioural Brain Research 209: 137-

41. South African Society for Basic and Clinical Pharmacology “Best Publication

Award, 2011”.

63. Liebenberg N, Harvey BH, Brand L, Brink CB (2010). Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression. Behavioural Pharmacology 21: 540-547.

64. Mokoena ML, Harvey BH, Oliver DW, Brink CB (2010). Ozone modulates the effects of imipramine on immobility in the forced swim test, and nonspecific parameters of hippocampal oxidative stress in the rat. Metabolic Brain Disease 25: 125-33.

65. Harvey BH, Duvenhage I, Viljoen F, Taljaard N, Malan SF, Wegener G, Brink CB, Petzer JP (2010). Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues. Biochemical Pharmacology 80: 1580-91.

66. Popplewell WL, Marais EA, Brand L, Harvey BH, Davies-Coleman MT (2010). Euphorbias of South Africa: Two new phorbol esters from Euphorbia bothae. South African Journal of Chemistry 63: 175–179.

32

67. Mokoena ML, Brink CB, Harvey BH, Oliver DW (2011). Appraisal of ozone as biologically active molecule and experimental tool in biomedical sciences. Medicinal Chemistry Research 20:1687–1695.

68. Güldenpfennig M, Wolmarans D, du Preez JL, Stein DJ, Harvey BH (2011). Cortico-striatal oxidative stress, dopamine turnover and relation with stereotypy in the deer mouse. Physiology and Behavior 103:404–411.

69. Abildgaard A, Solskov L, Volke V, Harvey BH, Lund S, Wegener G (2011). A high-fat diet exacerbates the depressive-like behavior in the FSL rat model of depression. Psychoneuroendocrinology 36: 623-633.

70. Mőller M, Du Preez JL, Emsley R, Harvey BH (2011). Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine administration. European

Neuropsychopharmacology 21:471–483. South African Academy of Pharmaceutical

Sciences “Best Publication Award in Pharmacology, 2012”.

71. Terre‟Blanche G, Heyer N, Bergh JJ, Mienie LJ, van der Schyf CJ,,Harvey BH (2011). The styrene metabolite, phenylglyoxylic acid, induces striatal-motor toxicity in the rat: Influence of dose escalation/reduction over time. Neurotoxicity Research 20:97-101.

72. Liebenberg N, Müller HK, Fischer CW, Harvey BH, Brink CB, Elfving B, Wegener G (2011). An inhibitor of cAMP-dependent protein kinase induces behavioural and neurological antidepressant-like effects in rats. Neuroscience Letters 498:158-61.

73. Hamer M, Malan NT, Harvey BH, Malan L (2011). Depressive symptoms and sub-clinical atherosclerosis in Africans: role of metabolic syndrome, inflammation and sympathoadrenal function. Physiology and Behavior 104 (2011) 744–748.

74. Swanepoel T, Harvey BH, Harden LM, Laburn HP, Mitchell D (2011). Dissociation between learning and memory impairment and other sickness behaviours in rats given fibroblast-stimulating lipopeptide-1 (FSL-1). Brain Behavior and Immunity 25:1607-1616.

75. Swanepoel T, Harvey BH, Harden LM, Laburn HP, Mitchell D (2012). Simulated recurrent Mycoplasma infection in rats induces recurrent sickness responses without residual impairment in spatial learning and memory. Physiology and Behaviour 105: 800–808.

76. Harvey BH, Shahid M (2012). Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: Focus on pharmacology and preclinical translational models. Pharmacology Biochemistry and Behavior 100:775-800.

77. Hamer M, Frasure-Smith N, Lespérance F, Harvey BH, Malan NT, Malan L (2012). Depressive Symptoms and 24-Hour Ambulatory Blood Pressure in Africans: The SABPA Study. International Journal of Hypertension 2012;2012:426803.

78. Malan L, Hamer M, Schlaich MP, Lambert GW, Ziemssen T, Reimann M, Van Rooyen

JM, Schutte R, Schutte AE, Fourie CMT, Harvey BH, De Geus JCN, Seedat YK, Malan NT (2012). Facilitated defensive coping, silent ischemia and ECG left ventricular hypertrophy: the SABPA Study. Journal of Hypertension 30:543-550.

33

79. Petzer A, Harvey BH, Wegener G, Petzer JP (2012). Azure B, a metabolite of methylene blue, is a high-potency, non-selective and reversible inhibitor of monoamine oxidase. Toxicology and Applied Pharmacology 258:403–409.

80. Moller M, Du Preez JL, Emsley RA, Harvey BH (2012). Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment. Neuropharmacology 62: 2499-2506.

81. Moller M, Du Preez JL, Harvey BH (2012). Development and validation of a single analytical method for the determination of tryptophan and its kynurenine metabolites in rat plasma. Journal of Chromatography B 898: 121-129.

82. Liebenberg N, Harvey BH, Brand L, Wegener G, Brink CB. (2012). Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats. Metabolic Brain Disease 27:337–340.

83. Brand L, van Zyl J, Minnaar EL, Viljoen F, du Preez JL, Wegener G, Harvey BH (2012). Cortico-limbic changes in acetylcholine and cGMP in the Flinders Sensitive Line rat, a genetic model of depression. Acta Neuropsychiatrica 24: 215–225.

84. Trabace L, Zotti M, Colaianna M, Morgese MG, Schiavone S, Tucci P, Wegener G,

Harvey BH, Cuomo V (2012). Neurochemical differences in two rat strains exposed to social isolation rearing. Acta Neuropsychiatrica 24: 286-295.

85. Harvey BH, Hamer M, Louw R, van der Westhuizen FH, Malan L (2013). Metabolic and glutathione redox markers associated with brain-derived neurotrophic factor in depressed African men and women. Evidence for counter-regulation? Neuropsychobiology 67:33-40.

86. Emsley R, Chiliza B, Asmal L, Harvey BH (2013). The nature of relapse in schizophrenia. BMC Psychiatry 13: 50.

87. Möller M, Du Preez JL, Berk M, Emsley RA, Harvey BH (2013). Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioral deficits in rats, and is reversed by clozapine or N- acetylcysteine. Brain Behavior and Immunity 30: 156-167.

88. Harvey BH (2013). The biology of behaviour. International Innovation, August, 18-20; http://www.research-europe.com/magazine/HEALTHCARE2/EF23/index.html.

89. Mashele N, Malan L, van Rooyen JM, Harvey BH, Potgieter JC, Hamer M (2013). Depression, cardiometabolic function and left ventricular hypertrophy in African men and women: The SABPA Study. Clinical and Experimental Hypertension 35: 213-9.

90. Wolmarans D, Brand L, Stein DJ, Harvey BH (2013). Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): Response to chronic escitalopram treatment and basal serotonin transporter (SERT) density. Behavioral Brain Research 256: 545-553.

34

91. Möller M, Du Preez JL, Viljoen FP, Berk M, Harvey BH (2013). N-acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats. Metabolic Brain Disease 28: 687-96.

92. Petzer A, Harvey BH, Petzer JP (2014). The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase. Toxicology and Applied Pharmacology 274: 488-93.

93. Mashele N, Malan L, van Rooyen JM, Harvey BH, Potgieter JC, Hamer M (2014). Blunted neuro-endocrine responses linking depressive symptoms and ECG left ventricular hypertrophy in black Africans: the SABPA study. Cardiovascular Endocrinology 3: 59-65.

94. Strauss L, Brink CB, Möller M, Stein DJ, Harvey BH (2014). Late-life effects of chronic methamphetamine exposure during puberty on behaviour and cortico-striatal monoamines in social isolation reared rats. Developmental Neuroscience 36: 18-28.

95. Davis J, Moylan S, Harvey BH, Maes M, Berk M (2014). Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries. Australian and New Zealand Journal of Psychiatry 48: 512-529.

96. Smith AJ, Malan L, Uys L, Ziemssen T, Harvey BH, Malan NT (2014). Down-regulated brain-derived neurotrophic factor (BDNF) is a cardiometabolic risk in Black Africans: The SABPA Study. Journal of Human Hypertension (in press).

97. Emsley R, Chiliza B, Asmal L, du Plessis S, Phahladira, L, van Niekerk Y, Janse van

Rensburg S, Harvey BH (2014). A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophrenia Research (in press).

98. Harvey BH, Slabbert FN (2014). New insights on the antidepressant discontinuation syndrome. Human Psychopharmacology (in press).

99. Slabbert FN, Harvey BH, Brink CB, Lubbe M (2014). Prospective analysis of the Medicine Possession Rate (MPR) of antidepressants in the private health sector of South Africa (2006 to 2011). South African Medical Journal (in press).

100.Slabbert FN, Harvey BH, Brink CB, Lubbe M (2014). The impact of major depressive disorder on compliance to antidepressant treatment in adult HIV/AIDS patients: A prospective study in a South African private health care cohort. AIDS Research and Therapy (submitted).

101.Mokoena L, Harvey BH, Viljoen F, Brink CB (2014). Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response. Psychopharmacology (submitted).

102.Delport A, Harvey BH, Petzer A, Petzer JP (2014). Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties. Life Sciences (submitted).

35

103.Brand S, Möller M, Harvey BH (2014). A review of biomarkers in mood and psychotic disorders: A dissection of clinical vs. preclinical correlates. Current Neuropharmacology (submitted).

104.Lochner C, McGregor N, Hemmings S, Harvey BH, Breet E, Swanevelder S, Stein DJ (2014). Symmetry symptoms in obsessive compulsive disorder: Clinical and genetic correlates. Genes Brain and Behavior (submitted).

ANNEXURE C:

CONTRIBUTIONS TO BOOKS

1. Harvey, BH (1998). Glutamate and nitric oxide: Mechanisms in lithium

associated relapse and refractoriness. In: The Biological and Clinical Actions of Lithium: New Perspectives, Becker, RW, Lucas, KC and Gallicchio, VS (Eds), Cheshire Press, Connecticut, USA, pp185-200; ISBN 0-9641073-5-X.

2. Harvey, BH, Meyer CL, Gallicchio VS (1999). The haemopoietic and immuno-

modulating action of lithium-salts: An investigation into the chemotherapy of

HIV infection in South Africa. In: Lithium-50 Years: Recent Advances in Biology and Medicine, Lucas, KC, Becker, RW and Gallicchio, VS (Eds), Weidner Publishing, Cheshire, Connecticut, USA, pp175-188; ISBN 0-9641073-9-2.

3. Stein DJ, Fineberg N, Harvey BH (2001). Unusual symptoms of obsessive

compulsive disorder. In: Obsessive-compulsive disorder: A practical guide. Fineberg N, Marrazziti D, Stein DJ (Eds), Dunitz, London, UK, pp 37-50; ISBN 1-84184 1749.

4. Stein DJ, Vythilingum B, Seedat S, Harvey BH (2003). Trichotillomania. In: Psychocutaneous Medicine. in Koo JYM, Lee C-S (ed.), Psychocutaneous Medicine. New York, NY, Marcel Dekker, Basel, Switzerland, pp 203-215; ISBN 0-8247-0979-9.

5. Harvey BH, Brink CB, Stein DJ (2005). Relevance of myo-inositol to the

neurobiology and treatment of obsessive-compulsive disorder. In: Obsessive-Compulsive Disorder Research; Ling, B (Ed); Nova Science Publishers Inc, New York, USA , p 67-91; ISBN: 1-59454-313-5.

6. Stein DJ, Seedat S, Carey P, Harvey BH (2005). Precursors, early detection, and

prevention of anxiety disorders. In: M Maj, Lopez-Ibor JJ, Sartorius N, Sato M, Okasha A (eds), Early Detection and Management of Mental Disorders, John Wiley and Sons, Chichester, UK, pp 231-248; ISBN: 0-470-01083-5.

7. Harvey BH (2005). Stress and the brain: A new challenge for psychopharmacology. North-West University, Potchefstroom, South Africa; ISBN 1-86822-472-4

8. Stein DJ, Harvey BH, Seedat S, Hollander E (2006). Treatment of impulse control

disorders. In: Hollander E, Stein DJ (Eds), Clinical Manual of Impulse Control Disorders, American Psychiatric Publishing, Inc, Arlington, VA, USA, ISBN 1-58562-136-6, pp309-325.

36

9. Harvey BH (2009). Major depression and metabolic encephalopathy: Syndromes

more alike than not ? In McCandless DW (Ed), Metabolic Encephalopathy, Springer Science+ Business Media, LLC, New York, USA, ISBN: 978-0-387-79109-8, pp 349-369.

10. Harvey BH (2011). Translational theory-driven hypotheses and testing are enhancing our understanding of PTSD and its treatment. In: Stein DJ, Friedman MJ, Blanco C (Eds), Post-traumatic stress disorder, John Wiley and Sons, Chichester, UK, ISBN 978-0-470-68897-7, pp139-141.

11. Harvey BH, Niehaus D (2012). The Neurobiology of Psychiatric Disorders. In: Roos L. Burns J (Eds), Textbook of Psychiatry, 2nd Edition, Oxford University Press, Cape Town, South Africa (in preparation).

ANNEXURE D:

POST-GRADUATE STUDENTS

MSc (completed)

1. A pharmacological and behavioral evaluation of locomotor behavior in the guinea pig Student: Andre Scheepers Supervisor: Prof BH Harvey Co-promoter: Dr L Brand 2. An investigation into neurotoxic mechanisms in haloperidol-induced tardive dyskinesia Student: Ans-Marie Bester Supervisor: Prof BH Harvey 3.Behavioral and neurochemical effects of acute and chronic antidepressant administration and withdrawal Student: Lucy Jonker (awarded with distinction) Supervisor: Prof BH Harvey 4.Pharmacological manipulation of serotonin 5HT2 receptor-mediated locomotor behavior Student: Rene Human Supervisor: Prof BH Harvey Co-promotor: Dr L Brand 5.Pharmacological and behavioural assessment of an animal model of post-traumatic stress disorder Student: Carla Naciti (awarded with distinction) Supervisor: Prof BH Harvey Co-supervisor: Dr L Brand 6.Aging as a contributory factor in the neurobiology of tardive dyskinesia Student: Ané Nel Supervisor: Prof BH Harvey

37

7.The effects of myo-inositol on muscarinic receptor expression and function Student: Lucille Viljoen (awarded with distinction) Supervisor: Prof BH Harvey Co-promotor: Dr CB Brink 8.Genetic polymorphism in dextromethorphan metabolism by CYP2D6 and CYP3A4 enzyme isoforms Student: Mzwai Mgwabi (awarded with distinction) Supervisor: Prof BH Harvey Co-promotor: Dr TG Goosen 9.The role of myo-inositol in G-protein coupled receptor-mediated sub-cellular transduction mechanisms in neuronal cell lines Student: Susan de Kock Supervisor: Dr CB Brink Co-promotor: Prof BH Harvey 10.Investigating the role of the NO-cGMP pathway in an animal model of post traumatic stress disorder (PTSD) Student: Tanya Bothma Supervisor: Prof BH Harvey Co-promotor: Dr L Brand 11.The role of the NO-cGMP pathway as a putative target in antidepressant action Student: Renche Retief Supervisor: Prof BH Harvey Co-promotor: Dr L Brand 12.A study into the role of monoamines in the pathology and pharmacology of post traumatic stress disorder (PTSD) in an animal model Student: Zakkiya Jeeva Supervisor: Dr L Brand Co-promotor: Prof BH Harvey 13.The modulating effect of myo-inositol and other antidepressants on the mRNA levels and activity of various enzymes in the phosphoinositide metabolic pathway Student: Marina van Rooyen Supervisor: Dr CB Brink Co-promotor: Prof BH Harvey 14.The role of alpha-2A-adrenergic receptor antagonism in the rapidity of onset of action and the therapeutic efficacy of antidepressant drugs Student: Kenny Khoza Supervisor: Dr CB Brink Co-promotor: Prof BH Harvey

15.The effects of sildenafil on muscarinic and serotonergic receptor function and on the behaviour of depressed rats and antidepressant treatment Student: Blen Eager Supervisor: Dr CB Brink Co-promotor: Prof BH Harvey

38

16.Investigating a pharmacological agent against tobacco smoke addiction using the rat as animal model Student: Linda Nel Supervisor: Dr G Terre‟Blanche Co-supervisor: Prof dr JJ Bergh Assisting supervisor: Prof BH Harvey 17.Studies on antidepressant action on the mRNA levels of enzymes involved in the phosphoinositide metabolic pathway in neuroblastoma cells Student: Izelle Grobler Supervisor: Prof CB Brink Co-supervisor: Prof BH Harvey. 18.The role of a2A-adrenergic receptor antagonism in therapeutic efficacy and onset of action of antidepressant drugs Student: Nico Liebenberg Study leader: CB Brink Co-study leader: BH Harvey 19.The behavioural effects of sildenafil in a genetic animal model of depression and modulation of antidepressant response Student: Hannes Clapton: Study leader: CB Brink Co-leader: BH Harvey 20 Investigation into a novel anti-oxidant approach to the treatment of tardive dyskinesia. Student: Charise Joubert Study leader: BH Harvey 21.A bio-behavioural investigation into the role of the cholinergic system in stress Student: Ilse Groenewald (awarded with distinction) Study Leader: L Brand Co-study leader: BH Harvey 22.Behavioural, pharmacological and neurochemical studies of social isolation rearing in rats Student: Carl Toua (awarded with distinction) Study Leader: BH Harvey Study co-leader: L Brand 23.The modulating effects selected antidepressants and related drugs on markers of cellular resilience in cultured human neuroblastoma cells Student: Leanie Potgieter (awarded with distinction) Study Leader: CB Brink Study Co-leader: BH Harvey 24.Investigating the role of AMPAkines in an animal model of post traumatic stress disorder (PTSD). Student: Eugene Hamlyn Study Leader: BH Harvey 25.Regional cholinergic and glutamatergic characterization of the Flinders Sensitive Line (FSL) rat and its normal control, the Flinders resistant Line( FRL) rat.

39

Student: P. Jurgen van Zyl (awarded with distinction) Study Leader: L Brand Study co-leader: BH Harvey 26.Regional neurochemical characterization of the Flinders Sensitive Line (FSL) rat and its normal control, the Flinders Resistant Line (FRL) rat with regard to glutamate-nitric oxide signalling pathways Student: Estella L Minnaar (awarded with distinction) Study Leader: L Brand Study Co-leader: BH Harvey 27.Oxidative status in rats exposed to social isolation rearing: Behavioral pharmacology studies and relevance for schizophrenia Student: Marisa Moller (awarded with distinction) Study Leader: BH Harvey 28.Regional brain oxidative status and dopamine turnover in the deer mouse, a putative animal model of obsessive compulsive disorder Student: Mariaan Guldenfennig (awarded with distinction) Study Leader: BH Harvey 29.Behavioural and neurochemical investigations on structural analogues of methylene blue as novel antidepressant drug candidates Student: Ingrid Duvenhage Study Leader: BH Harvey Study Co-leader: SF Malan; Assisting study-leader: Jacques Petzer 30.A clinical study investigating the correlation between depressed mood, and markers of oxidative stress, following two acute stressors Student: Mellissa Watson Study Leader: Linda Brand Study co-leader: BH Harvey 31.The effects of sildenafil on anxiety-like behaviour and markers of neuroplasticity in rats Student: F Naude Slabbert Study Leader: CBB Brink Assistant study-leader: BH Harvey 32.The effect of early life exposure of stress-sensitive rats to the serotonin-norepinephrine reuptake inhibitor venlafaxine on behavior in adulthood Student: Stephan Steyn (awarded with distinction) Study leader: CB Brink Study assistant leaders: Prof BH Harvey

33.Stereotypical behavior in the deer mouse (peromyscus maniculatis bairdii): A pharmacological investigation of the frontal cortical striatal serotonergic system Student: Dewet Wolmarans (awarded with distinction) Study Leader: BH Harvey Assistant study-leader: L Brand

34.Involvement of monoaminergic systems in conditioned fear: Implications for post traumatic stress disorder

40

Student: Madeleine Erasmus (awarded with distinction) Study leader: BH Harvey Study assistant leaders: L Brand 35.Role of nitric oxide and the insulin-peroxisome proliferator-activated nuclear receptor-γ (PPAR-γ) pathway in mood regulation and antidepressant action Student: Sarel Brand Study leader: BH Harvey Assistant study leaders: Prof CB Brink and G Wegener 36. Cortical brain release of glutamate by ketamine and fluoxetine: An in vivo microdialysis study in the Flinders Sensitive Line Rat Student: Gert Visser Study Leader: L Brand Study co-leader: BH Harvey 37. Effects of chronic metamphetamine exposure during early or late phase development in normal and social isolation reared rats. Student: Laeticia Strauss (with distinction) Study leader: BH Harvey Study co-leader: CB Brink

MSc (in progress) 1.The effect of early-life administration of metamphetamine on anxiety-related behavior later in life in stress-sensitive and control rats. Student: Cecilia Swart Study leader: CB Brink Study co-leader: BH Harvey 2. Brain-derived neurotrophic factor (BDNF) and Structural Vascular Disease in a Black African cohort: The SABPA Study Student: Aldus J Smith Study leader: L Malan Assistant study-leader: BH Harvey 3. The effect of early-life exposure of rats to venlafaxine on behavior and neurobiological markers of antidepressant action in adulthood. Student: Renier Kruger Study leader: Prof CB Brink Assistant study leader: Prof BH Harvey 4. Antidepressant properties of azure B and a synthetic analogue of methylene blue. Student: Anzelle Delport Study leader: Prof J Petzer Study co-leader: Prof BH Harvey

PhD (completed)

41

1.The involvement of nitric oxide in a rodent model of post traumatic stress disorder Student: Frasia Oosthuizen Supervisor: Prof BH Harvey Co-supervisor: Prof L Brand 2. A molecular and pharmacological study of stress-evoked changes on markers of cellular resilience in rat brain Student: Ane Korff Supervisor: Prof BH Harvey Assistant supervisor: Prof CB Brink 3.Molecular and pharmacological studies into a putative animal model of obsessive compulsive disorder: Peromyscus maniculatus bairdii Student: Shaun Korff Supervisor: Prof BH Harvey Assistant supervisor: Dr F van Westhuizen.

4. The inhibition of phosphodiesterase type 5 as a novel target for antidepressant action

Student: Nico Liebenberg Supervisor: Prof CB Brink Co-supervisor: Prof BH Harvey 5.The role of prostaglandins and cytokines in simulated recurrent Gram-positive bacterial infection Student: Tanya Swanepoel Supervisor: Prof Duncan Mitchell (Wits) Co-supervisor: Prof BH Harvey 6. Behavioural, neurochemical, inflammatory and neuroanatomical markers following social isolation rearing in rats before and after select drug intervention. Student: Marisa Moller Study Leader: BH Harvey Assistant supervisors: JL du Preez and RA Emsley

PhD (in progress) 1. The modulating effects of acute and chronic inhaled ozone on the antidepressant-like and central neuromodulatory effects of imipramine in rat Student: Lilly Mokoena Study Leader: CB Brink Study Co-leader: BH Harvey

2. Cardiometabolic and mental health profile of urban black Africans: The SAPBA Study. Student: Nyiko Mashele Supervisor: Prof Leone Malan Co-supervisor: Prof BH Harvey 3. A retrospective analysis of antidepressant non-compliance and discontinuation and the long term effects thereof in the private health-care sector of South Africa. Student: F Naude Slabbert Supervisor: Prof M Lubbe Co-supervisor: Prof BH Harvey

42

4. Development and validation of an animal model of treatment resistant depression. Student: Sarel Brand Supervisor: Prof BH Harvey Co-supervisor: Prof L Brand 5. Behavioral, molecular and neurochemical characterization of a novel α2C-receptor antagonist in selected translational animal models of psychiatric illness. Student: Madeleine Erasmus Supervisor: Prof BH Harvey Assistant Supervisor: Prof L Brand

Post-doctoral students (completed): A molecular and anatomical assessment of stress-evoked changes in brain of animal models of stress and depression Student: Dr Kennita Thinyane Supervisor: Prof BH Harvey

ANNEXURE E:

APPOINTMENTS AS EXTERNAL EXAMINER

1. Undergraduate Programs:

External examiner and moderator, B.Pharm (4th year), Rhodes University, Grahamstown, Nov 2001. External examiner and moderator, B.Pharm (4th year), University of the North, Pietersburg, Nov 2001.

2. Postgraduate Programs:

MSc: Mr PH Parmar “An investigation into the possible neuroprotective role of melatonin in copper-loading” MSc thesis written under the direction of Prof Santy Daya, Dept of Pharmacology, Rhodes University, Grahamstown; February 2001. MSc: Miss C Petersen “The role of corticotropin releasing factor in anxiety disorders” MSc thesis written under the direction of Dr Willie Daniels, Dept of Medical Physiology, Stellenbosch University, Tygerberg; September 2001. MSc: Miss SMJ Hemmings

“The genetic aetiology of obsessive-compulsive disorder: Investigating the roles of selected

genes encoding components in the serotonergic and dopaminergic pathways” MSc thesis written under the direction of Dr Valerie Corfield, MRC Center for Molecular and Cellular Biology, Stellenbosch University, Tygerberg; October 2001.

MSc: Miss Lelanie Richter “The effect of central administration of corticotropin-releasing factor on the behaviour and neurochemistry of rats.”

43

MSc thesis written under the direction of Prof Willie Daniels, Dept of Medical Physiology, Stellenbosch University, Tygerberg; December 2003. MSc: Mrs GLS Lelaka “Study of the effects of methylphenidate (Ritalin) in an animal model for attention-deficit hyperactivity disorder-The spontaneously hypertensive rat.” MSc thesis written under the direction of Prof Vivienne Russell, Dept of Human Biology, University of Cape Town, Cape Town; September 2004. MSc: Mrs S van Zyl “Evaluation of N,N‟-disubstituted 1,3-diaminopropran-2-ols for anti-HIV activity.” MSc thesis written under the direction of Prof Sarel Malan, School of Pharmacy, North West University, Potchefstroom; August 2004. PhD: Miss L Cassim “Malatonin and anticancer therapy: Interactions with 5-fluorouracil” PhD thesis written under the direction of Prof Santy Daya, Faculty of Pharmacy, Rhodes University, Grahamstown, August 2007. PhD: Miss Olivia M Dean “Investigating the role of glutathione depletion in schizophrenia: Animal models and clinical investigations” PhD thesis written under the direction of Prof Michael Berk, Department of Psychiatry, University of Melbourne, Australia. PhD: Ms Lelanie Marais “The potential of exercise to reverse stress induced abnormalities in the rat brain.” PhD thesis written under the direction of Prof Willie Daniels, Dept of Medical Physiology, University of Kwa-Zulu Natal, November 2009. PhD: Miss Megan Anne Jones “The causes and consequences of stereotypic behavior in the striped mouse, RHABDOMYS”. Prof Neville Pillay, School of Animal, Plant and Environmental Sciences, University of the Witwatersrand, Johannesburg, South Africa, April 2012.

ANNEXURE F:

EDITORIAL BOARD MEMBERSHIP OF PROFESSIONAL JOURNALS:

1. Metabolic Brain Disease (Springer), an international peer-review journal. 2. African Journal of Psychiatry, a local, but international peer-review journal.

3. Neuropsychiatric Disease and Treatment (Dove Press), an international peer-review

journal. The journal is the official journal of the International Neuropsychiatric Association.

4. Human Psychopharmacology: Clinical and Experimental (Wiley), an international peer-review journal.

5. Review editor for Frontiers in Psychopharmacology, an international peer-review electronic journal.

44

6. Acta Neuropsychiatrica (Wiley), an international peer-review journal.

7. Psychiatry Journal (Hindawi), an international peer-reviewed, open access journal

8. Open Clinical Chemistry Journal (Bentham), an international peer-reviewed, open

access journal

9. Recent Patents on CNS Drug Discovery (Bentham), an international peer-review journal.

ANNEXURE G:

INVITATIONS AND APPOINTMENTS 1. Invitation from the editorial board of Reviews in Contemporary Pharmacotherapy

(Marius Press, Carnforth, UK; Johnson S, Johnson FN, Eds), to participate in a composite review on the mechanism of action of lithium, with special emphasis on the role of essential fatty acids and cyclic nucleotide balance. Two papers were published in 1993 (see Annexure B).

2. Invitation from the Dept of Biochemistry, University of the North, Pietersburg, Rep of

South Africa, to deliver a series of lectures on the 28th of September 1994. The following addresses were given:

“The L-arginine-nitric oxide pathway: A brief over-view.” and

“Lithium actions on cyclic nucleotide second messengers and nitric oxide:

Therapeutic and toxicological implications.” 3. Invitation from the Department of Medical Biochemistry, University of Stellenbosch,

Parow, to deliver an address on the 10th February 1995 entitled “Nitric oxide:

Physiology and pathology”. 4. Invitation from the Department of Pharmaceutical Sciences, Rhodes University,

Grahamstown, to deliver an address on the 19th September 1995 entitled “The role

of the pharmacist in the management of depression” 5. Invitation from the Department of Pharmacy, University of Port Elizabeth, Port

Elizabeth, to deliver an address on the 20th September 1995 entitled “The role of the

pharmacist in the management of depression”. 6. Invitation to present a lecture at a bi-annual forum for psychiatrists, neurologists and

diagnostic radiologists at Constantiaberg Medi-Clinic, Cape Town, on 10 November

1995 entitled “Nitric oxide: Function and application”. 7. Invitation from the department of Psychiatry, University of Natal, Durban, to present a

lecture on the 21st November 1995 entitled “The comparative pharmacology of the

serotonin selective reuptake inhibitors”.

8. Invitation by the East Cape Sub-Group of the Society of Psychiatrists of South Africa

to present a lecture on the 7th October 1995 entitled “The comparative

pharmacology of the serotonin selective reuptake inhibitors”.

45

9. Invitation from Dr C Allwood, Scientific Editor for the South African Medical Journal, to prepare a comparative overview of the neurobiology and pharmacological management of depression, with special emphasis on new generation anti-depressants. The paper was published in 1997 (see Annexure B).

10. Invitation by the International Society for Lithium Research to chair an academic

session at the Lithium-South Africa Congress, Berg-en-Dal, Kruger National Park, 1-6 September 1997.

11. Invitation from Eli Lilly (SA) PTY Ltd to present a training module at their national

sales conference entitled “Clinical Pharmacology of the Serotonin Receptor:

Functional and Therapeutic Role in the CNS”, Champagne Sports Resort, Drakensberg, 26 January, 1999.

12. Appointed program leader within the Drug Research and Development focus area at

the PU for CHE, in 1999. 13. Invitation from the Biological Psychiatry Group of South Africa to present a plenary

paper at their biannual Psychiatry Congress, with the theme “Psychopharmacology

into the New Millennium”, entitled “New Generation Antipsychotics: Integrating the

pharmacology and neuropathology of schizophrenia”, Spier Estate, Stellenbosch, 26-28 May 1999.

14. Invitation by the International Society for Lithium Research to chair an academic

session at the Lithium-Lexington Congress, University of Kentucky, Lexington, Kentucky, USA, 7-11 May 1999.

15. Invited by the Indian Academy of Neuroscience to present a guest lecture at the 18th

Annual Conference of the Indian Academy of Neuroscience in Lucknow, India from

the 29-31st January 2001, entitled “Distinct early and late neurochemical events in

the pathogenesis and severity of tardive dyskinesia”. However, due to an increase in teaching load in the BPharm under-graduate and Honours degree program, I was obliged to turn this invitation down.

16. Invited visiting guest lecturer at the College of Pharmacy, University of Kentucky,

Lexington, Kentucky, USA, 08 May 2001. The following presentation was delivered:

"Distinct early and late neurochemical events in the pathogenesis and severity

of neuroleptic-induced tardive dyskinesia".

17. Academic session chairman at the Congress of the International Society of

Immunopharmacology, 17th-21st September 2001, Sun City, South Africa. 18. Invited by one of the Editors of Psychopharmacology Bulletin, Dr Husseini K Manji, to

prepare a review paper on the role of lithium in the treatment of AIDS and AIDS-

related dementia. The paper, entitled “Lithium salts in AIDS and AIDS-related

dementia”, was published in 2002 (see publication list).

19. Appointed by Pfizer to the Ziprasidone Advisory Board, together with other leading South African psychiatrists and neuroscientists. The purpose of this advisory panel is to provide scientific and clinical expertise in the evaluation and treatment of

46

schizophrenia, and to use this expertise to guide Pfizer‟s efforts in the appropriate and

ethical marketing of ziprasidone (Geodon), a new atypical antipsychotic agent.

20. Invitation to chair an academic session at the 12th National Psychiatry Congress of

South Africa, 24th – 27th September 2002, Somerset West, Western Cape, South Africa.

21. Invited to present a guest lecture, entitled “Stress, depression and neurodegenerative

pathology: New clues to treatment?”, at the Third International Conference on

Pharmaceutical and Pharmacological Sciences, 22-25 September 2002, Boksburg, Gauteng, South Africa.

22. Elected to Fellowship of the Collegium Internationale Neuro-Psychopharmacologicum

(CINP) in 2001. 23. Invited by the Editors of Current Psychiatry Reports to prepare a review paper on new

developments in pre-clinical models of anxiety disorders. The paper, entitled “Pre-

clinical models of anxiety disorders”, was published in August 2003 (see Annexure B-publication list).

24. Appointed to the Evaluation Committee for Research at the North-West University,

2000-2002 (Universiteitstoetsingskommissie), responsible for reviewing strategic innovation fund applications and, secondly, ensuring quality of research output and long-term viability of research focus areas within the university.

25. Appointed to the peer-review board of the South African Medical Research Council

(MRC) in 2001. 26. Appointed to the peer-review panel for Health Sciences, at the National Research

Foundation, responsible for the evaluation and grading of scientists at national level, 2006-8.

27. Appointed co-director for Animal Models Research at the MRC Unit on Anxiety and

Stress Disorders, University of Cape Town, South Africa, in 2002. This appointment is still active.

28. Invited by Dr Gregers Wegener to spend a 3 week research visit at the Institute for

Basic Psychiatric Research, Department of Biological Psychiatry, University of Aarhus, Denmark, in June-July 2003. During this period, a guest lecture, entitled

“Stress and neurodegenerative pathology as determinants of the clinical course

of depression” was also delivered to researchers and academics of this institute. 29. Invited by the International Scientific Program Committee of the 24th Congress of the

Collegium Internasionale Neuropsychopharmacologicum (CINP) to participate as a speaker in a synthesia entitled: "New strategies for improving response to

antidepressant drugs", with a presentation entitled: "The neurobiology of

antidepressant withdrawal: linking compliance to treatment response or

relapse". The congress will be held in Paris, France, from 20-24 June 2004. 30. Invited by the publishers, Nova Science Publishers, New York, USA, to contribute a

chapter for a volume entitled “Progress in Obsessive-compulsive Disorders

Research” due for publication in late 2004. A chapter entitled “Relevance of myo-

47

inositol to the neurobiology and treatment of obsessive-compulsive disorder” has since been submitted and accepted for inclusion into this volume.

31. Invited by the editors of Neuropsychiatric Disease and Treatment to write a review

paper entitled “Role of nitric oxide as inflammatory mediator in post-traumatic

stress disorder (PTSD): Evidence from an animal model”, Neuropsychiatric Disease and Treatment 1: 109-124.

32. Invited to write an editorial on the latest research on lithium salts in psychiatry for

South African Psychiatry Review entitled "Lithium: Priming the next 50 years" (South African Psychiatry Review 2004; 7: 12).

33. Invited by the International Scientific Program Committee of the 25th Congress of the

Collegium Internasionale Neuropsychopharmacologicum (CINP) to chair a symposium

entitled “The role of the nitric oxide-cGMP pathway in mood and stress-related

disorders: implications for understanding their biology and treatment”, and also to participate as a speaker in the session. The congress will be held in Chicago, USA, from 9-13 July 2006.

34. Invited to present a guest lecture, entitled “Stress and the brain: A new challenge

for psychopharmacology”, at the Dept of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 20th September 2005.

35. Invited by Prof Vera Klenerova, Institute of Medical Biochemistry, Charles University,

Prague, Czech Republic, to present a guest lecture on the 15th December 2006,

entitled “Role of nitric oxide in post traumatic stress disorder”, to researchers and academics of this institute.

36. Invited by Dr Glenda MacQueen, Director of the Mood Disorders Program, Dept of

Psychiatry & Behavioral Neurosciences, McMaster University, Hamilton, ON, Canada,

to present a guest lecture on the 13th July 2006, entitled “Adaptive plasticity during

stress and depression: A new challenge for psychopharmacology”, to researchers and academics of this institute.

37. Invited by Bristol Myers Squibb SA to deliver a key note address at the South African

launch of Abilify (aripiprazole), a new antipsychotic agent, entitled “Aripiprazole:

Role of partial agonism and its relevance in psychiatry”, at the Midrand Conference Center, Johannesburg, South Africa, on the 22nd March 2006.

38. Invited by the South African Society Psychiatrists of South Africa to present a plenary

talk at their annual congress held on the 10-14 September 2006 at the Royal Swazi

Sun, Swaziland, entitled: Investigating the role of the glutamate-nitric oxide

pathway in post traumatic stress disorder: Studies using time-dependent

sensitisation. 39. Invited by the South African Biological Psychiatry Society of South Africa to present a

plenary talk at their annual congress held on the 25-28 February 2007 at the Lord

Charles Hotel, Somerset West, Cape Town, South Africa, entitled “Reactive nitrogen

and oxygen intermediates and oxidative stress in neuroleptic-induced tardive

dyskinesia: Implications for prevention and treatment.

48

40. Invited by the World Federation of Societies of Biological Psychiatry to co-chair a session on “PTSD: The state of the art” at the 2nd International Congress of Biological Psychiatry held on the 17-21 April 2007 in Santiago, Chile, and to present a plenary

talk entitled “Time-dependent sensitization: Validation for PTSD and effects on

arousal, aversive memory and altered hippocampal/cortical muscarinic

cholinergic receptor status.” However, immediately prior to the congress, illness prevented me from attending this meeting.

.

41. Appointed by Servier to the Agomelatine Advisory Board. The purpose of this advisory panel is to provide scientific and clinical expertise in the evaluation and treatment of depression, and to use this expertise to guide Servier‟s efforts in the appropriate and ethical marketing of agomelatine, a new class of antidepressant.

42. Invited by Prof Luigia Trabace, Dept of Biomedical Sciences, University of Foggia,

Foggia, Italy, to present a guest lecture on the 23rd April 2008, entitled “Reactive

nitrogen and oxygen intermediates and oxidative stress in neuroleptic-induced

tardive dyskinesia”, to researchers and academics of this institution. 43. Appointed to the South African National Committee for the International Brain

Research Organisation (IBRO). 44. Invited by Dr Mohammed Shahid, Dept of Pharmacology, Organon Ltd, Glasgow,

Scotland, UK, to present a guest lecture on the 28th April 2008, entitled “Studying

posttraumatic stress disorder using time-dependent sensitisation”, to researchers and academics of this institution.

45. Invited to present a plenary talk at the Danish Society of Biological Psychiatry

Symposium on Novel Insights in the Pathophysiology of Psychiatric Disorders, 12 September 2008, University of Aarhus, Aarhus, Denmark, entitled “Non-compliance and inappropriate antidepressant discontinuation and implications for the neurobiology and longitudinal outcome of depression. “BH Harvey.

46. Invited to present a plenary lecture at the IUPAR Integrated Organ Systems

Pharmacology School for Africa entitled “Development and validation of illness-specific animal models of relevance for neuro-psychopharmacology”, 19-22 September 2009, Potchefstroom, South Africa.

47. Invited presentation at a symposium on the Biomedical Pathophysiology Relevant to

Stress and Disease, entitled “Possible Resilience and Susceptibility Factors Related to Oxidative Stress and the Development of Depression in Male and Female Black

Africans: The SABPA study. Harvey BH, Malan L, Hamer, M, Potgieter JC, Schutte AE, Schutte R, Huisman HW, Van Rooyen JM, Fourie CMT. 68th Annual meeting of the American Psychosomatic Society, Maritime Hotel, Portland, Oregon, USA. 11-13 March 2010.

48. Invited research report presented at the Agomelatine Master Class Symposium hosted

by Servier Pharmaceuticals, 10-13th February 2010, Paris, France, entitled

“Antidepressant discontinuation and the benefits of agomelatine”. Harvey BH.

49. Invited by the Collegium Internasionale Neuropsychopharmacologicum (CINP) to present a plenary lecture at the CINP Psychopharmacology course, Johannesburg (2-3rd April 2011) and Cape Town (12-14th Nov 2010), South Africa.

49

50. Invited to contribute a chapter entitled “The Neurobiology of Psychiatric Disorders” in

Textbook of Psychiatry 2nd edition and published by Oxford University Press, due for publication in 2013.

51. Invited to write an authorative review on the role of glutamate receptors and glutamate

signalling in anxiety disorders for a special issue of the noted international peer review journal, Pharmacology, Biochemistry and Behaviour (see Harvey and Shahid 2011 in publication list).

52. Invited to write a commentary on the neurobiology of PTSD recently published in

“Trauma and Mental Health: Resilience and Posttraumatic Disorders”, a Wiley-Blackwell publication under the auspices of the American Psychiatric Association (see Harvey 2011 in list of books).

53. Invitation from the noted international journal, Psychiatric Clinics of North America, to

prepare a review paper on animal models of OCD (see Korff and Harvey 2006 in list of publications).

54. Invited lecture at the Center for Psychiatric Research, University of Aarhus, Aarhus,

Denmark, on the 30th March 2012, entitled “Neurochemical, peripheral and behavioural

effects of social isolation rearing in rats: Relevance for schizophrenia”, Harvey BH.

ANNEXURE H:

INVITATIONS TO PEER REVIEW 1. International Journals:

Cellular and Molecular Neurobiology

Neuropsychopharmacology

Journal of Gastroenterology and Hepatology

Brain Research

Life Sciences

Metabolic Brain Disease

CNS Spectrums

Acta Pharmacologica Sinica

Pharmacology Biochemistry and Behaviour

Developmental Brain Research

Psychotherapy and Psychosomatics

Nature Reviews Genetics

Biological Psychiatry

Pharmacological Research

Human Psychopharmacology

Neuropsychiatric Disease and Treatment

Behavioral Brain Research

Journal of Psychopharmacology

Physiology and Behavior

50

Journal of Pharmacy and Pharmacology

Stress

Depression and Anxiety

Psychiatry Research

European Neuropsychopharmacology

International Journal of Neuropsychopharmacology

Pharmacology Biochemistry and Behaviour

Journal of Affective Disorders

Neuropsychiatric Disease and Treatment

Trends in Pharmacological Sciences (TiPS)

Pharmacological Reports

International Journal of Developmental Neuroscience

World Journal of Biological Psychiatry

Psychiatry Research-Neuroimaging

South African Journal of Botany

Progress in Neuropsychopharmacology and Biological Psychiatry

Southern African Journal of Child and Adolescent Mental Health

African Journal of Psychiatry

Progress in Neurobiology

Acta Neuropsychiatrica

Brain Behaviour and Immunity

Cellular and Molecular Neurobiology

Psychopharmacology

Frontiers in Pharmacology

Neuroscience and Biobehavioral Reviews

Molecular Psychiatry

2. Referee for the National Research Foundation (NRF), to peer-review research

protocols and applications submitted for research funding/grants. 3. Member of the South African Medical Research Council (MRC) Peer Review Board

responsible for reviewing research proposals submitted to the MRC.

4. Reviewer for submitted abstracts for presentation at the Congress of the

International Society of Immunopharmacology, 17th-21st September 2001, Sun City, South Africa.

5. Peer reviewer for the Israeli Science Foundation. 6. Peer reviewer for the Netherlands Organization for Scientific Research. 7. Peer reviewer for the Scientific Foundation of Ireland.

51

ANNEXURE I:

GRANTS AND AWARDS

Recipient of independent research grants from the SA Medical Research Council towards central nervous system research from 1999-2003, 2004-2006 and 2008-2010.

Recipient of a four-year grant from the National Research Foundation, 2002-2005, and again 2006-1010, for studies into stress-related disorders.

Awarded independent research grants for 2001 and 2002 from the National Research Foundation for research on HIV-dementia and tardive dyskinesia.

Recipient of a travel grant from the SA Medical Research Council to attend an academic meeting in Lexington, Kentucky, USA (May 1999).

Recipient of a travel grant from the National Research Foundation for a research visit to the Chandler Medical Center, University of Kentucky, USA (May 1999).

Recipient of an unrestricted research grant from Norgine (SA) towards clinical research into establishing the role of lithium salts in AIDS (May 1999).

Recipient of an International Brain Research Organization (IBRO) bursary to attend the Congress of the Federation of European Neuroscience Societies (FENS) in England from the 24th to 28th of June 2000.

Awarded a “Poster Award” for researchers under 40 years, at the Collegium Internasionale Neuro-Psychopharmacologicum (CINP) Congress in Brussels, Belgium, July 2000. The title of my paper: “Chronic inositol modulates 5HT2 and D2 receptor function in the guinea pig striatum: A behavioral study towards a therapeutic role in OCD”.

Awarded the South African Academy of Pharmaceutical Sciences “Best Publication Award in Pharmacology in 2001, 2002, 2004, 2006, 2009, 2010 and 2011.

Awarded the South African Society for Basic and Clinical Pharmacology “Best Publication Award” in 2005, 2009 and 2011.

A number of my students win the Young Scientists Award by the South African Society for Basic and Clinical Pharmacology (see Local congress presentations).

Recipient of an International Union of Pharmacology (IUPHAR) Travel Award to attend the World Congress of Pharmacology in San Francisco, USA, from the 7th to 12th July 2002.

Awarded the Janssen-Cilag Best Publication Award in the Faculty of Health

Sciences, North-West University, for the paper entitled “NMDA receptor

involvement in imipramine withdrawal-associated effects on swim stress,

GABA levels and NMDA receptor binding in rat hippocampus”, published in Life Sciences (2002) 71: 43-54.

52

Recipient of independent research grant from the University of Aarhus, Aarhus, Denmark, to conduct research into the behavioral pharmacology of methylene blue and its synthetic analogues (2008-10).

Recipient of independent research grant from the University of Melbourne, Barwon Health, to conduct research into the use of the N-acetyl cysteine in translational animal models of tardive dyskinesia (2006-8) and schizophrenia (2013-15).

In 2012 I received the FARMOVS prize for pharmacology and drug development from the Suid Afrikaanse Akademie vir Wetenskap en Kuns (South African Academy of Arts and Science).

Recipient of independent research grant from Lundbeck, Denmark, to conduct research into the behavioral pharmacology of escitalopram in the deer mouse model of obsessive compulsive disorder (2008-12), in collaboration with the University of Cape Town who managed the funds.

Recipient of independent research grant from the University of Aarhus, Aarhus, Denmark, to conduct research into the behavioral pharmacology of methylene blue and its synthetic analogues (2008-10).

Recipient of intra-mural funds from the South African MRC to conduct research on methamphetamine, under the auspices of the Brain Research and Innovation Network (BRAIN), with its center at the Department of Psychiatry, University of Cape Town (2011-13).

53

ANNEXURE J:

INTERNATIONAL AND NATIONAL COLLABORATORS AND RESEARCH

AGREEMENTS Past and present collaborative research interactions with prominent scientists, both locally and abroad, are indicated below. In particular, the various studies with Proff Stein, Berk, Emsley and Dr Wegener, have now attained major significance, as can be seen by the published output and congress presentations generated from work originating from these collaborative efforts (see Annexure A and B).

Local: Prof Dan J Stein MRC Unit on Anxiety and Stress Disorders, Dept of Psychiatry, University of Cape Town, Observatory,South Africa e-mail: dan.stein@uct.ac.za I am co-director of the MRC Unit on Anxiety and Stress Disorders, and co-investigator with Prof Stein in the Brain Research and Innovation Network (BRAIN). Prof Duncan Mitchell Brain Function Research Group, School of Physiology, University of the Witwatersrand, 7 York Road, Johannesburg, South Africa e-mail: duncan.mitchell@wits.ac.za Prof Jacques Petzer, Division of Pharmaceutical Chemistry, North-West University, Potchefstroom. email: Jacques.Petzer@nwu.ac.za Prof Leone Malan, Hypertension in Africa Research Team, Division of Physiology, North-West University, Potchefstroom email: leone.Malan@nwu.ac.za Prof Robin Emsley, Dept of Psychiatry, University of Stellenbosch, Tygerberg, Cape Town, South Africa. e-mail: rae@sun.ac.za

International: Dr Gregers Wegener Institute for Basic Psychiatric Research, Department of Biological Psychiatry, University of Aarhus, Skovagervej 2, DK-8240 Risskov, Denmark e-mail: wegener@dadlnet.dk Prof Michael Berk Mental Health Research Institute of Victoria, University of Melbourne, Australia e-mail: MIKEBE@BarwonHealth.org.au Dr Mo Shahid Orion Pharma, Turku, Finland. e-mail: Mo.Shahid@orionpharma.com

54

Prof Luigia Trabace Department of Biomedical Sciences, University of Foggia, Foggia, Italy. e-mail: trabace@unifg.it Dr David H. Overstreet Bowles Center for Alcohol Studies, University of North Carolina, Chapel Hill, USA e-mail: dhover@med.unc.edu Dr Mark Hamer Department of Epidemiology and Public Health, University College of London, UK. e-mail: m.hamer@ucl.ac.uk Dr Connie Sánchez Morillo, Lundbeck AG, Copenhagen, Denmark. e-mail: cs@lundbeck.com